

CURRICULUM VITAE
CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE
Updated: 11 FEB 2017

PERSONAL INFORMATION

Name: Cohen, Jeffrey Alan
Date of birth: October 14, 1954
Place of birth: Durham, NC
Citizenship: US

Office Address: Mellen Center U-10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
Office Phone: (216) 445-8110
E-mail: cohenj@ccf.org
Facsimile: (216) 445-6259

Home Address: 5033 Boulder Creek Drive, Solon, OH 44139
Home Phone: (440) 498-9461
Marital Status: Married, Sally Farwell
Children: Jennifer, Joshua

EDUCATION

Connecticut College, New London, CT	BA	1972-1976
University of Chicago, Chicago, IL	MD	1976-1980

POST-GRADUATE TRAINING

University of Pennsylvania, Philadelphia, PA	Medicine Internship	1980-1981
University of Pennsylvania, Philadelphia, PA	Neurology Residency	1981-1984
University of Pennsylvania, Philadelphia, PA	Immunology Fellowship	1984-1987

PROFESSIONAL APPOINTMENTS

Assistant Professor	Department of Neurology, University of Pennsylvania	1987
Associate Director	Comprehensive MS Center, University of Pennsylvania	1987-1991
Member	Cancer Center, University of Pennsylvania	1987-1994
Member	Neuroscience Graduate Group, University of Pennsylvania	1988-1994
Director	Comprehensive MS Center, University of Pennsylvania	1991-1994
Member	Immunology Graduate Group, University of Pennsylvania	1993-1994
Staff	Mellen MS Center, Neurological Institute, Cleveland Clinic,	1994-present
Director	Experimental Therapeutics Program, Mellen MS Center	1994-present
Medical Director	Neuroscience Clinical Research Office	2000-2002
Professor	Medicine, Cleveland Clinic Lerner College of Medicine	2006
Member	National Center for Regenerative Medicine	2008-present
Professor	Division of General Medical Sciences, Case Western Reserve University – secondary appointment	2011
Director	Mellen MS Center, Neurological Institute, Cleveland Clinic	2014-present

CERTIFICATION AND LICENSURE

Boards: Neurology	1985
Licensure: Ohio 35-066469	1994-present
Pennsylvania MD-026517E	1980-1994

HONORS/AWARDS

1973 Freshman Chemistry Award, Connecticut College

1974	Sophomore Zoology Award, Connecticut College
1975	Junior Zoology Award, Connecticut College
1975	Winthrop Scholarship Award, Connecticut College
1976	Phi Beta Kappa, Connecticut College
1980	Alpha Omega Alpha, University of Chicago
1988	Clinician-Investigator Development Award, NINDS
1994	Distinguished Alumnus, Connecticut College
1996-7	Best Doctors in America: Midwest Region
1996-present	Top Doctors, Cleveland Magazine
1998-present	Best Doctors in America
1998	American Neurological Association
2001	Health Professional of the Year, Ohio Buckeye Chapter, National MS Society
2002-present	Castle Connolly America's Top Doctors
2007	Volunteer Hall of Fame, Health Professionals/Researchers, National MS Society
2008	Top Doctors and featured profile, Northern Ohio Live Magazine
2011	Profile in Lancet Neurology 2011;10:504
2011	Nomination for the Cleveland Clinic Sones Award for Innovation
2012	Nomination for the Cleveland Clinic Sones Award for Innovation
2013	Nomination for the Cleveland Clinic Sones Award for Innovation
2013	Cleveland Super Doctor
2013	Fellow of the American Neurological Association
2014	Hazel Prior Hostetler Endowed Chair
2014	Nomination for the Cleveland Clinic Sones Award for Innovation
2015	Nomination for the Cleveland Clinic Sones Award for Innovation
2016	National MS Society Volunteer Hall of Fame – Scientific Research
2016	Nomination for the Cleveland Clinic Sones Award for Innovation

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Current:

American Academy of Neurology	1982-present
American Neurological Association	1998-present

Previous:

American Association for the Advancement of Science
 American Federation for Clinical Research
 American Medical Association
 American Society for Microbiology
 American Society for Neurological Investigation
 International Society for Interferon and Cytokine Research
 International Society for Neuroimmunology
 New York Academy of Sciences
 Philadelphia County Medical Society
 Philadelphia Neurological Society
 Society for Neuroscience

PROFESSIONAL SERVICE

Journal Editor

Co-Editor, Multiple Sclerosis Journal – Experimental,
Translational and Clinical

2014-present

Editorial Boards

Lancet Neurology

2017-present

Journal Manuscript Reviewer:

Acta Neurologica Scandinavica
Annals of Neurology
Arthritis and Rheumatism
Brain, Behavior, and Immunity
British Journal of Pharmacology
Cellular Immunology
Clinical Immunotherapeutics
Clinical Investigation
Cognitive and Behavioral Neurology
DNA and Cell Biology
European Journal of Neurology
European Journal of Neuroscience
European Neurology
Future Medicine
International Journal of Cancer
JAMA Neurology
Johns Hopkins Advanced Studies in Medicine
Journal of Allergy and Clinical Immunology
Journal of Interferon and Cytokine Research
Journal of Neurochemistry
Journal of Neuroimmunology
Journal of the Neurological Sciences
Journal of Neurology
Lancet
Lancet Neurology
Mayo Clinic Proceedings
Multiple Sclerosis Journal
Multiple Sclerosis and Related Disorders
Muscle and Nerve
Nature Reviews Neurology
Neurology
Neuroradiology
New England Journal of Medicine
Proceedings of the National Academy of Sciences
Regional Immunology

Grant Review

Ad hoc reviewer, Neurobiology, VA Merit Review Board	1989
Member, Neurobiology, VA Merit Review Board	1990-1993
Member, Postdoctoral Fellowship Review Committee, National MS Society	1995-2001
Chair, Clinical Fellowship Review Committee, National MS Society	2002-2010
Ad hoc reviewer, Health Research Awards, Ireland	2010
Ad hoc reviewer, Research Grants, National MS Society	2011
Ad hoc reviewer, NIDCR/NIH clinical trial planning applications	2012
Member, NIAID Autoimmune Centers of Excellence Special Emphasis Panel	2013
Ad hoc reviewer, UK Medical Research Council	2013
Member, Department of Defense, Congressionally Directed Medical Research Programs MS Research Program Integration Panel	2014-present
Ad hoc reviewer, MS Research Australia	2014
Ad hoc reviewer, Scotland Chief Scientist Office	2014
Canadian Research Chairs Review Committee	2015-present
Ad hoc reviewer, Hertie MS Chair applications	2016
Ad hoc reviewer, International Progressive MS Alliance, Collaborative Network Award Program	2016

Data Safety Monitoring Boards

Chair, OvIFN-0102 Phase 2 trial DSMB, Pepgen	2003-2006
Member, RTL1000 DSMB	
Member, MAESTRO-02 Phase 3 trial of MBP8298 DSMB, BioMS	2007-2009
Chair, NeuroVax DSMB, Orchestra Therapeutics	2006-2007
Member, DAIT/NIAID Autoimmune DSMB	2013-present
Member, MESEMS DSMB	2014-present

Other Review Committees

Ad Hoc Member, NINDS Board of Scientific Counselors	2016
---	------

Advisory Groups

Examiner, Neurology Boards, American Board of Psychiatry and Neurology	1989-1993
National MS Society (local chapter):	
Member, Clinical Advisory Committee, Greater Delaware Valley Chapter	1990-1994
Member, Healthcare Advisory Committee, Ohio Buckeye Chapter	1994-present
Chair, Clinical Advisory Committee, Ohio Buckeye Chapter	1995-2004
Research Advocate, Ohio Buckeye Chapter	1996-1998
Member, Board of Trustees, Ohio Buckeye Chapter	1997-present
Consulting Neurologist, Ingliss House, Philadelphia, PA	1993-1994
Consultant/Advisory Committee Member:	
RW Johnson, Neurologic toxicity of OKT3	1991
RW Johnson, Standardization of EDSS for cladribine trial (2-CDA-MS-001)	1994
Viragen, Natural interferon-alpha to treat MS	1994
Teva, Development of Copaxone to treat MS	1995
Zeneca, Adhesion molecule inhibitors to treat MS	1995
Mucos Pharma GmbH, Oral enzymes to treat MS	1996
Hoechst, Marion, Roussel, Intramyelinic edema potentially due to vigabatrin	1996
Teva-Marion Partners, Development of Copaxone to treat MS	1996
Otsuka America, Vesnarinone to treat MS	1997
Leukosite/Millennium, Campath-1h to treat MS	1998-2001
Astra, ATM-027 to treat MS	1998
Medtronic, Intrathecal growth factors to treat MS	2000

Acorda, Fampridine-SR to treat MS	2000-2004
ABI, Recombinant alpha fetoprotein to treat MS	2001-2002
Acorda, Neuregulins to treat MS	2002
Acorda, Anti-IP10 monoclonal antibody to treat MS	2003
Centocor, Anti-IL12 monoclonal antibody to treat MS	2003
Millenium, Anti-CCR2 monoclonal antibody to treat MS	2003
Vertex, IMPDH inhibitor to treat MS	2003
Clinical Expert Report for Biogen Idec and FDA on Protocol C-850	2004
Wyeth, Temsirolimus to treat MS	2005
Incyte, CCR2 antagonist to treat MS	2005
Merck, Neuroprotective strategies to treat MS	2004
Novartis, FTY720 to treat MS	2005
Peptimmune, CO-14 to treat MS	2005
UCB, Anti-IL17 monoclonal antibody to treat MS	2005
UCB, Integrin antagonist to treat MS	2005
Genzyme, Campath-1h to treat MS	2005-present
Serono, Oral cladribine to treat MS	2005-2007
Eisai, Glutamate receptor antagonist to treat MS	2006
Genentech, Rituximab and ocrelizumab to treat Devic's syndrome	2006
GlaxoSmithKline, Oral alpha-4 integrin antagonist to treat MS	2006
Schering Plough, Oral alpha-4 integrin antagonist to treat MS	2006
IMPAX, CR Baclofen to treat spasticity in MS	2006-2007
Eli Lilly, KA328 and LA426 to treat MS	2006
Genentech, Rituximab and ocrelizumab to treat MS	2007
Teva, pharmacogenomic assessment of Copaxone response	2009-present
Novartis, fingolimod mechanism of action	2009-2012
Five-Prime, FP-1069 to treat MS	2010
Eli Lilly, Ly2439821 anti-IL17 MAb to treat MS	2010-2011
Elan, emerging MS treatments	2010
Synthon, generic glatiramer acetate GTR to treat MS	2010-present
Vaccinex, VX15/2503 to treat MS	2011-2015
Receptos, selective S1P receptor modulator RPC1063 to treat MS	2011-present
Innate Immunotherapeutics, MIS416 to treat MS	2012-present
Novartis, brain atrophy effects of fingolimod	2012-2013
Athersys, MultiStem to treat MS	2013-2015
Endece, NDC-1308 to treat MS	2013-present
Adamas, ADS-5102 (amantadine HCl) to treat MS	2014-present
Genentech, ocrelizumab to treat MS	2015
Merck, multiple sclerosis treatment	2016
Case Western Reserve University Stem Cell Ethics Roundtable	2010-2011
MS Outcome Assessments Consortium	2012-present

COMMITTEE SERVICE

National and International

American Academy of Neurology	Member, Medical Student Essay Committee	1991-1997
	Councilor, MS Section	1998-2000
	Member, Abstract Review Committee	2002-2009
	Member, Education Committee, MS Section	2003-2006
National MS Society	Member, Clinical Advisory Board	1995-present
	Member, Executive Committee, Clinical Advisory Board	2002-2012

	Member, Professional Education Committee	1997-2013
	Chair, Professional Education Committee	2002-2008
	Member, Task Force on CNS Repair	2003
	Member, Steroid Therapy Task Force	2005-2008
	Chair, Task Force on Clinical Training Programs	2008
National MS Society and ECTRIMS	Member, International Advisory Committee on Clinical Trials	1999-present
	Chair, International Advisory Committee on Clinical Trials	2012-present
	International Panel on MS Differential Diagnosis	2006-2007
	International Panel on MS Diagnostic Criteria	2010
ACTRIMS	Member, Board of Governors	1998-2014
	Member, Annual Meeting Planning Committee	1998-2012
	Chair, 2014 ACTRIMS-ECTRIMS Combined Meeting Program Committee	2012-2014
	Member, Board of Directors	2012-2015
	Member, 2016 Annual Meeting Program Committee	2015-2016
	Member, 2017 Annual Meeting Program Committee	2016-2017
	Member, Board of Directors	2016-present
	President Elect	2016-2019
Devics Study Group	Member, Steering Committee	1998-2002
Sylvia Lawry Center for MS Research	Member, Clinical Trials Working Group	2001-2002
Multiple Sclerosis International Federation	National MS Society Representative, International Medical and Scientific Board	2014-present
	Member, IMSB Executive Team	2014-present

Cleveland Clinic

	Member, Neurology Residency Selection Committee	1994-2001
	Member, Neuroscience Grant Review, RPC, Lerner Research Institute	1996-2001
	Member, Neurology Clinical Research Task Force	1999
	Member, Clinical Research Division Committee	2001-2004
	Member, Medical Division Committee	2005-2006
	Member, Mellen Center Search Committee	2006-2008
	Member, Neurological Institute Research Committee	2006-2012
	Member, Mellen Center Business Plan Task Force	2008
	Member, Mellen Center Follow-up Visit Access FasTrac	2008-2009
	Member, Mellen Center Knowledge Project Steering Committee	2009-present
	Member, Cellular Therapeutics Task Force	2010-2014
	Chair, Neurological Institute, Academic Performance Metrics Task Force	2011-2015
	Member, Neurological Institute Research Council	2012-present
	Member, Neurological Institute, Appointments and Promotions Committee	2014-present
	Member, Innovations Life Sciences Peer Review Committee	2016-present
	Member, Neurological Institute Seed Funding Task Force	2016-present

Cleveland Clinic Lerner College of Medicine

Member, Committee on Appointments and Promotions 2009-present
Member, Provost's Dean Review Committee 2012-2013

Educational Committees

Chair, Infectious Disease Fellowship Internal Review Committee 2006
Member, Neurological Institute Education Committee 2010-present
Member, Neurological Institute Fellowship Committee 2014-2015

Other (Institutions before CCF)

Neurology Department Univ. Pennsylvania:
Member, Program Development Committee 1989-1991
Member, Neuro-oncology Search Committee 1989-1991
Member, Ambulatory Care Committee 1990-1991
Member, Neurology Database Committee 1990-1991
Member, Residency Selection Committee 1991
Member, Neurovirology Search Committee 1991-1992
Member, Compensation Plan Committee 1992
Member, CME Committee 1992
Member, Cognitive Neurology Search Committee 1992-1993
Member, Resident Research Award Committee 1993-1994

TEACHING ACTIVITIES

Curriculum/Course Development

1. AAN Course Director, MS and its masquerades: diagnostic dilemmas, 1998-2001

Presentations (outside lectures by invitation)

1987

Immunopathogenesis of CNS lupus, University of Pennsylvania symposium - CNS Involvement in SLE, Philadelphia, PA, 9/30/87

1988

Introduction to myasthenia gravis, Delaware Valley Myasthenia Society, Philadelphia, PA, 11/20/88

1989

Research in Multiple Sclerosis, Central Pennsylvania Chapter of the National MS Society, Allentown, PA, 3/22/89

Clinical trials of Copolymer-1 in MS, Annual meeting, Greater Delaware Valley Chapter of the National MS Society, Philadelphia, PA, 11/2/89

1990

Copolymer-1 in MS, Neurology Grand Rounds, Pennsylvania Hospital, Philadelphia, PA, 3/22/90

Virus receptors, anti-receptor antibodies, and brain function, Department of Psychiatry, University of Miami, Miami, FL, 5/1/90

Viral receptors, anti-receptor antibodies, and glial biology, Kroc Symposium in Neurology, Department of Neurology, University of Connecticut, Farmington, CT, 6/1/90

Viral receptors and neurological disease, Neurology Grand Rounds, University of Colorado, Denver, CO, 7/18/90

Diagnosing and treating multiple sclerosis, Departments of Neurology University of Pennsylvania course Neurology for the 1990's Philadelphia, PA, 11/7/90

Use of the reovirus model for studies of anti-idiotypic anti-receptor antibodies, Neuroimmunology / Microbiology Seminar, University of Alabama, Birmingham, AL, 11/13/90

Oncogenes and anti-oncogenes for the neurologist, Neurology Grand Rounds, University of Alabama, Birmingham, AL, 11/14/90

The reovirus system as a model for studies of ligand-receptor interactions, Neuroimmunology Seminar, Wayne State University, Detroit, MI, 11/29/90
Oncogenes and anti-oncogenes for the neurologist, Neurology Grand Rounds, Wayne State University, Detroit, MI, 11/30/90

1991

Virus receptors, anti-receptor antibodies and neurologic disease, Neurology Grand Rounds, Louisiana State University, New Orleans, LA, 1/11/91
Multiple sclerosis, Medical Management Conference, Graduate Hospital, Philadelphia, PA, 2/7/91
American Academy of Neurology Annual Meeting Session Chair, T-cell receptors and myelin genes, 4/25/91
Multiple sclerosis, Continuing Medical Education Program, Warren Hospital, Phillipsburg, NJ, 5/1/91
Dialogue with the doctor, Greater Delaware Valley Chapter, National MS Society, Lankenau Hospital, Philadelphia, PA, 6/11/91
Expression of the neu gene by proliferating Schwann cells in peripheral, nerve development, degeneration, and tumorigenesis, Peripheral Nerve Study Group, Arden House, NY, 7/1/91
Update on diagnosis, treatment, and research in MS, Annual Meeting, Multiple Sclerosis Service Organization, West Orange, NJ, 10/6/91
Update on diagnosis, treatment, and research in MS, Annual Meeting, Central Pennsylvania Chapter, National MS Society, Scranton, PA, 10/18/91
Update on diagnosis, treatment, and research in MS, Annual Meeting, Delaware Chapter, National MS Society, Centerville, DE, 10/27/91
Introduction to neuroimmunology I, Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, 12/6/91
Copolymer 1 in the treatment of multiple sclerosis, Neurology Grand Rounds, Christiana Hospital, Wilmington, DE, 12/12/91
CNS vasculitis, Neurology Grand Rounds, Lehigh Valley Hospital Center, Allentown, PA, 12/13/91
Introduction to neuroimmunology II, Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, 12/20/91

1992

Introduction to neuroimmunology III, Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, 1/17/92
Dialogue with the doctor, Greater Delaware Valley Chapter, National MS Society, Suburban General Hospital, Norristown, PA, 6/3/92
Steroids in MS: The controversy, Annual Meeting, Mid-Jersey Chapter, National MS Society, Freehold, NJ, 11/8/92
Multiple sclerosis symptoms, Annual Meeting, Greater Delaware Valley Chapter, National MS Society, Philadelphia, PA, 11/11/92

1993

Role of oncogenes and anti-oncogenes in glial cell biology, The Susan Hellams Memorial Lecture, Central Virginia Chapter of the Society for Neuroscience, Richmond, VA, 3/19/93
Neurologic complications of immunosuppressive therapy, Dinner seminar: Neurologic aspects of organ transplantation, Annual Meeting of American Academy of Neurology, New York, NY, 4/25/93
Dialogue with the doctor, Greater Delaware Valley Chapter, National MS Society, Nazareth Hospital, Philadelphia, PA, 6/14/93
Copolymer-1 in the treatment of multiple sclerosis, Neurology Grand Rounds, The Cleveland Clinic Foundation, Cleveland, OH, 8/11/93
Introduction to neuroimmunology I, Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, 10/1/93
Introduction to neuroimmunology II, Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, 10/8/93
Introduction to neuroimmunology III, Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, 10/15/93
Clinical Case Conference, Department of Medicine, Graduate Hospital, Philadelphia, PA, 10/20/93

Chief of Medicine Conference, Department of Medicine, The Medical Center at Princeton, Princeton, NJ, 10/28/93

The other research story: oral myelin, Cop 1, and 4-AP, Annual Meeting, Greater Delaware Valley Chapter, National MS Society, Philadelphia, PA, 11/4/93

1994

Cardiopulmonary manifestations of CNS disease, Neurology Grand Rounds, Pennsylvania Hospital, Philadelphia, PA, 2/17/94

The care of patients with multiple sclerosis. Clinical, research, social, and personal issues, Distinguished Alumni Lecture Series, Connecticut College, New London, CT, 3/9/94

New developments in the diagnosis and treatment of MS, MS Support Group, Strongsville, OH, 6/2/94

New developments in the treatment of MS, New headquarters dedication, Multiple Sclerosis Association of America, Akron, OH, 9/8/94

Overview of clinical aspects of multiple sclerosis, Medicine Grand Rounds, Southside Medical Center, Youngstown, OH, 10/20/94

1995

Introduction to multiple sclerosis, Paramedic Education Series, Akron City Hospital, Akron, OH, 2/21/95

Therapeutics in multiple sclerosis: The old and the new, Selected Aspects of Clinical Neurology, Course sponsored by the Department of Neurology, Cleveland Clinic, Cleveland, OH, 2/25/95

American Academy of Neurology Annual Meeting Session Chair, MR spectroscopy in MS, 5/10/95

New developments in the treatment of MS, NW Cleveland MS Support Group, NEO-NMSS, North Olmsted, OH, 6/14/95

Copolymer-1 in the treatment of relapsing MS, NMSS-sponsored conference Advances in the diagnosis and treatment of multiple sclerosis Boston, MA, 6/20/95

Update on the treatment of MS, Westside Friendship Group - MS Support Group, Cleveland, OH, 9/19/95

Assessing progression: MRI, clinical, and functional status, Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, Las Colinas, TX, 11/18/95

1996

Assessing progression: MRI, clinical, and functional status, Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, St. Petersburg, FL, 2/3/96

Assessing progression: MRI, clinical, and functional status, Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, Rancho Mirage, CA, 2/17/96

Neurological aspects of MS, Northeast Ohio NMSS sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 3/7/96

Update: Emerging therapies, Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, Las Colinas, TX, 3/17/96

Copaxone (Copolymer-1) in the treatment of multiple sclerosis IRC-sponsored conference Multiple sclerosis: Implications of basic research and clinical trial results, Boston, MA, 5/14/96

Update on therapy for multiple sclerosis, Northwest Ohio MS Support Group, 5/16/96

Update on therapy for multiple sclerosis, Huron County Ohio MS Support Group, 7/18/96

The neurological aspects of MS, Northeast Ohio NMSS sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 9/12/96

Emerging therapies for MS, Annual Meeting, Southwest Ohio Chapter, National MS Society, Dayton, OH, 10/5/96

Emerging therapies for MS, Neurology Grand Rounds, Wayne State University, Detroit, MI, 10/25/96

Emerging therapies for MS, Annual Meeting, Greater Michigan Chapter, National MS Society, Detroit, MI, 10/26/96

Consideration of new drugs to control relapses - Copolymer-1, Univ. of Maryland-sponsored symposium The Comprehensive Management of MS, Baltimore, MD, 11/8/96

Update: Emerging therapies for progressive MS, Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, Las Colinas, TX, 11/17/96

1997

Comparison of disease-modifying treatments for relapsing MS, Central Ohio Neurological Society, Columbus, OH, 2/20/97

New drugs for multiple sclerosis, Cleveland Clinic Department of Neurology sponsored course, Selected aspects of clinical Neurology, Cleveland, OH, 3/1/97

The neurological aspects of MS, Northeast Ohio Chapter of the National MS Society sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 3/6/97

Management of spasticity in MS, Central Ohio Neurological Society, Columbus, OH, 3/19/97

Update: Emerging therapies for progressive MS Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, Atlanta, GA, 3/23/97

Multiple sclerosis and other immune-mediated disorders American Academy of Neurology Course 226 Neurologic complications in pregnancy women, Boston, MA, 4/14/97

Overview of the diagnosis and treatment of MS Northeast Ohio Chapter of the National MS Society sponsored conference MS: Clinical update, Cleveland, OH, 5/2/97

Management of spasticity in multiple sclerosis, Toledo Neurological Society, Toledo, OH, 5/21/97

Overview of the diagnosis and management of MS, Cleveland Eastside MS Support Group, 6/25/97

Roundtable discussion on the management of spasticity, Athena Neurosciences sponsored conference, Philadelphia, PA, 7/21/97

Neurological aspects of MS, Northeast Ohio Chapter of the National MS Society sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 9/4/97

Update on multiple sclerosis, Medicine Grand Rounds, Mt. Sinai, Cleveland, OH, 10/22/97

Copaxone therapy for relapsing MS, Southwest Ohio Neurological Society, Dayton, OH, 10/23/97

Treatment of MS. Where we have been and where we are going, Annual meeting, Northeast Ohio Chapter, National MS Society, Cleveland, OH, 10/27/97

Treatment of multiple Sclerosis, MCO Department of Neurology-sponsored conference Hot topics in Neurology, Toledo, OH, 11/8/97

The treatment of relapsing MS. The role of Copaxone, Neurology Grand Rounds, MCO, Toledo, OH, 11/12/97

Immunotherapies for relapsing MS: The Copaxone experience, Berlex-sponsored conference Multiple Sclerosis: Clinical Issues and Decisions, Las Colinas, TX, 11/23/97

MRI in multiple sclerosis, Neurology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 12/12/97

1998

Neurological aspects of MS, Northeast Ohio Chapter of the National MS Society sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 3/10/98

Treatment approaches for nonresponders, CCF-sponsored conference Emerging concepts in the pathogenesis of MS, Cleveland, OH, 3/14/98

MS and its masquerades, American Academy of Neurology course 3BS.006, Minneapolis MN, 4/27/98

Emerging concepts in the treatment of MS, Neurology Grand Rounds, IU, Indianapolis, IN, 5/7/98

Natural progression in MS: To treat or not to treat, Biogen-sponsored conference Current concepts in the diagnosis and management of multiple sclerosis, Chicago, IL, 7/8/98

Comparison of disease modifying agents, Biogen-sponsored conference A patient centered therapeutic framework for multiple sclerosis: An international conference on models of care, Dallas, TX, 8/6/98

Changing concepts in MS pathogenesis, PMR Grand Rounds, Metro Hospital, Cleveland, OH, 9/28/98

The scientific basis of immunotherapies in MS, Annual meeting of the Consortium of MS Centers, Cleveland, OH, 10/3/98

Emerging concepts in MS treatment, Medicine Grand Rounds and Visiting Professor of the Month, Northeast, Ohio Universities College of Medicine, Canton, OH, 10/7/98

Neurological aspects of MS, Northeast Ohio Chapter of the National MS Society sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 10/7/98

Scoring the EDSS, PROMISE trial investigators meeting, Chicago, IL, 10/9/98

Management of MS, Family Practice Grand Rounds, Fairview Hospital, Cleveland, OH, 10/28/98

Reliability of the quantitative MS functional composite, Inservice, Biogen, Cambridge, MA, 11/2/98

Management of Spasticity in MS, Athena-sponsored dinner seminar, Lexington, KY, 11/11/98

Evolving concepts in the pathogenesis of MS, Neurology Grand Rounds, Univ. of Kentucky, Lexington, KY, 11/12/98

Perspectives for new therapeutic approaches to multiple sclerosis care, Serono-sponsored symposium Use of imaging and other monitoring measurements in multiple sclerosis treatment strategies, Santa Fe, NM, 11/22/98

1999

Changing concepts in MS pathogenesis: Implications for therapy, Neurology Grand Rounds, Univ. of Penn., Philadelphia, PA, 1/21/99

Course Director, AAN Course 2BS.007 MS and its masquerades: Diagnostic dilemmas Toronto, Ontario, Canada, 4/18/99

Multiple Sclerosis, AAN Course 6PC.003 Neurologic complications of pregnant women, Toronto, Ontario, Canada, 4/22/99

Outcome measures in MS clinical trials. EDSS and the MS Functional Composite, Consortium of MS Centers Annual meeting, Kansas City, MO, 5/14/99

Update on immunotherapy in MS, Consortium of MS Centers Annual meeting, Kansas City, MO, 5/15/99

Brain atrophy in MS. Rationale for early treatment, Biogen-sponsored satellite conference at the annual meeting of the European Neurological Society, Milan, Italy, 6/6/99

Neurological aspects of MS, Northeast Ohio Chapter of the National MS Society sponsored conference Moving forward. A program for newly diagnosed clients, Cleveland, OH, 9/29/99

Composite functional measures, CCF-sponsored International School on MS, Cleveland, OH, 10/21/99

Changing concepts in MS pathogenesis. Implications for management, Neurology Grand Rounds, LSU, New Orleans, LA, 10/22/99

Changing concepts in the treatment of MS, Annual meeting, Louisiana Chapter, National MS Society, New Orleans, LA, 10/23/99

Changing concepts in the treatment of MS, Teva Marion-sponsored dinner seminar, Baton Rouge, LA, 10/23/99

MS therapy for the new millennium, Univ. of South Florida-sponsored course The changing seasons of Multiple sclerosis, Hot Springs, VA, 10/31/99

Brain atrophy in MS, Penn. State College of Medicine/Geisinger Medical Center-sponsored symposium Multiple Sclerosis. Current concepts and management for the millenium Hershey, PA, 11/13/99

Retrospectively analyzed data, Teva Marion-sponsored roundtable Clinical trial design and disability measures New York, NY, 12/11/99

2000

Update on MSFC validation and IMPACT, Biogen-sponsored faculty update, Santa Fe, NM, 2/4/00

Multiple sclerosis, AAN Course 2PC.004 Neurologic crossfire San Diego, CA, 4/30/00

American Academy of Neurology Annual Meeting Session Chair, Phase I studies in MS, 5/1/00

Course Director, AAN Course 3BS.002 MS and its masquerades: Diagnostic dilemmas San Diego, CA, 5/1/00

Update on research in MS, Annual Research Night, Eastern North Carolina Chapter, National MS Society, Raleigh, NC, 6/7/00

Historical perspective on MS, Annual Educational Seminar on Multiple Sclerosis, Kym Sellers Foundation, Cleveland, OH, 8/26/00

Cyclophosphamide. Its clinical effects in MS, Charcot Foundation-sponsored ECTRIMS satellite conference Immunosuppression revisited, Toulouse, France, 9/6/00

Symptom management in MS, American Academy of Neurology and National MS Society-sponsored course Treatment of MS: Update 2000, New York, NY, 11/11/00

Update on the treatment of secondary progressive MS, Philadelphia Neurological Society, Philadelphia, PA, 11/29/00

2001

Results of IMPACT, Biogen Faculty Update, Palm Springs, CA, 2/23/01

Brain atrophy in MS, NMSS-sponsored symposium Neuronal injury in MS and related disorders New Orleans, LA, 3/19/01

Results of IMPACT, Biogen European advisory meeting, Paris, France, 4/22/01

American Academy of Neurology Annual Meeting Session Chair, MRI and MRS in MS I, 5/10/01

Results of IMPACT, Biogen French advisory meeting, Philadelphia, PA, 5/10/01

Results of IMPACT, Biogen Scandinavian advisory meeting, Philadelphia, PA, 5/10/01
Course Director, AAN Course 7BS.007 MS and its masquerades: Diagnostic dilemmas Philadelphia, PA, 5/11/01
Existing evidence for the treatment of secondary progressive MS, Mellen Center-sponsored symposium
Comprehensive MS care in the era of disease modifying therapy, Cleveland, OH, 6/15/01
IMPACT study results, Biogen-sponsored ECTRIMS satellite symposium, Dublin, Ireland, 9/13/01
Update on the pathogenesis and treatment of MS, Neurology Grand Rounds, Univ. of MI, Ann Arbor, MI, 10/10/01
Overview of the MSFC, Investigators meeting for Biogen 1801 and 1802 studies, Orlando, FL, 10/23/01
Overview of the MSFC, Investigators meeting for Biogen 1801 and 1802 studies, Vienna, Austria, 11/8/01
Making the diagnosis of MS, Medicine Grand Rounds, Fairview Hospital, Cleveland, OH, 12/17/01

2002

American Academy of Neurology Annual Meeting Session Chair, MS: Therapeutic trials I, 4/16/02
Interferon-beta treatment of secondary progressive MS, Neurology Grand Rounds, Univ. of Cincinnati, Cincinnati, OH, 5/21/02
Update on multiple sclerosis, Annual meeting, Ohio Buckeye Chapter, National MS Society, Columbus, OH, 10/28/02

2003

Rationale and design of ACT, Biogen Faculty Update, St. Petersburg, FL, 1/18/03
American Academy of Neurology Annual Meeting Session Chair, MS: Clinical trials I, 4/1/03
Review of the ACT protocol, ACT Investigators Meeting, Fort Lauderdale, FL, 5/21/03
Overview of the MSFC, ITN STAYCIS Investigators Meeting, Reston, VA, 11/5/03

2004

Update on ACT, Biogen Idec Faculty Meeting, Boca Raton, FL, 2/7/04
Overview of MS pathogenesis, Abbott Investigators Meeting, Laguna Beach, CA, 3/12/04
Overview of the EDSS and MSFC, Abbott Investigators Meeting, Laguna Beach, CA, 3/13/04
Review of the ACT protocol, ACT Investigators Meeting, Boston, MA, 3/23/04
Overview of the EDSS, ACT Investigators Meeting, Boston, MA, 3/23/04
Overview of MS pathogenesis, Abbott Investigators Meeting, Prague, Czech Republic, 4/2/04
Overview of the EDSS and MSFC, Abbott Investigators Meeting, Prague, Czech Republic, 4/3/04
American Academy of Neurology Annual Meeting Session Chair, MS: Imaging II, 4/29/04
Update on ACT and lessons learned, Meeting of Biogen Idec sponsored investigators, La Jolla, CA, 9/11/04
Rationale for the use of Tysabri (natalizumab) in MS, MS News, Mellen Center-sponsored program, Cleveland, OH, 12/13/04

2005

Overview of the EDSS, Genentech HERMES Investigators' meeting, Hollywood, FL, 1/7/05
American Academy of Neurology Annual Meeting Session Chair, MS: Outcomes, 4/12/05
TNF and demyelinating diseases, TNF and Beyond, CCF-sponsored conference, Cleveland, OH, 8/27/05
New CNS signs and symptoms in a patient on TNF inhibitors, TNF and Beyond, CCF-sponsored conference, Cleveland, OH, 8/28/05

2006

Review of 9006 study results, Teva 9006 Investigators Meeting, San Diego, CA, 4/4/06
American Academy of Neurology Annual Meeting Session Chair, MS: Clinical outcomes, 4/6/06
Future directions in MS clinical trials, Canadian Congress of Neurological Sciences, Montreal, Canada, 6/17/06
Review of 9006 study results, Teva 9016 European Investigators' Meeting, Madrid, Spain, 6/27/06
Overview of the MSFC, Teva 9016 European Investigators' Meeting, Madrid, Spain, 6/27/06
Rationale for the use of Tysabri (natalizumab) in MS and review of efficacy results, Mellen Center-sponsored program, Cleveland, OH, 7/18/06
Review of 9006 study results, Teva 9016 US Investigators' Meeting, Philadelphia, PA 7/26/06

Overview of the MSFC, Teva 9016 US Investigators' Meeting, Philadelphia, PA, 7/26/06
Update on ACT, Biogen Idec Investigators Meeting, La Jolla, CA, 9/16/06

2007

Results of ACT, Biogen Idec Faculty Meeting, Newport Beach, CA, 2/10/07
Protocol review, Novartis FTY 2302 Investigators Meeting, Miami, FL, 3/2/07
Results of ACT, Biogen Idec Investigators Meeting, Charleston, SC, 3/17/07
American Academy of Neurology Annual Meeting Session Chair, MS Clinical Trials II, 4/29/07
ACTRIMS Annual Meeting Session Chair, Washington, DC, 6/2/07
Overview of the MSFC, Teva MS-LAQ-301 Investigators Meeting, Hollywood, FL, 10/27/07

2008

Overview of the MSFC and contrast sensitivity, Teva MS-LAQ-302 Investigators Meeting, Rome, Italy, 2/27/08
Overview of the MSFC and contrast sensitivity, Teva MS-LAQ-302 Investigators Meeting, Orlando, FL, 4/5/08
American Academy of Neurology Annual Meeting Session Chair, MS Clinical Trials I, Chicago, IL, 4/14/08
American Academy of Neurology Contemporary Clinical Issues Plenary Session, IL-2 blockade to treat MS, Chicago, IL, 4/15/08
Imaging: OCT, Teva Multiple Sclerosis Round Table, Phoenix, AZ, 4/26/08
Future of MS treatments, Teva Sanofi-Aventis International Symposium on MS, Vienna, Austria, 5/24/08
Redirecting lymphocytes to treat MS, FOCIS course Interventional Immunology, Boston, MA, 6/5/08
Current and future treatments of MS, INOS, Silverado, CA, 6/12/08
Emerging therapies for MS, USF CME course Progress in Understanding Multiple Sclerosis and Parkinson Disease, Kiawah, SC, 7/12/08
Use of the visual system to monitor MS, USF CME course Progress in Understanding Multiple Sclerosis and Parkinson Disease, Kiawah, SC, 7/12/08
TV interview on BRAVO study and Bike MS 2008, Monica Robins, WKYC Channel 3 Cleveland, OH, 7/29/08
TV interview on BRAVO study and Bike MS 2008, Alicia Booth, WEWS Channel 5 Cleveland, OH, 8/1/08
Review of fingolimod safety data, Novartis fingolimod investigators' meeting, Montreal, Canada, 9/16/08
ECTRIMS/ACTRIMS Meeting, Session Chair, Young investigators, Montreal, CN, 9/17/08
Changing concepts in MS treatment, Annual Meeting, Ohio Buckeye Chapter, National MS Society, Akron, OH, 10/11/08

2009

MS: Current concepts and emerging therapies, Huron Hospital Medicine Grand Rounds, Cleveland, OH, 3/9/09
Update on natalizumab and PML, Course 2AC.003 Clinical Issues in MS, American Academy of Neurology, Seattle, WA, 4/26/09
MRI is not useful to monitor MS in clinical practice, Course 2AC.003 Clinical Issues in MS, American Academy of Neurology, Seattle, WA, 4/26/09
American Academy of Neurology Annual Meeting Session Chair, MS Clinical Outcomes, Seattle, WA, 4/28/09
ACTRIMS Annual Meeting Session Chair, Atlanta, GA, 5/30/09
Research update: stem cells and oral medications, Annual Meeting, Ohio Buckeye Chapter, National MS Society, Independence, OH, 11/12/09
Evolving concepts of multiple sclerosis, Neurology Grand Rounds, University of Virginia, Charlottesville, VA, 12/18/09

2010

Fingolimod. Biogen Idec National Faculty Meeting, Miami, FL 1/31/10
Results of the TRANSFORMS core study and extension. FTY Investigators' Meeting, Dallas, TX, 3/16/10
Results of the TRANSFORMS core study and extension. FTY Investigators' Meeting, Berlin, Germany, 3/23/10

American Academy of Neurology Annual Meeting Session Chair, MS Clinical Trials I, Toronto, CN, 4/13/10
Emerging oral therapies for MS. Consortium of MS Centers, San Antonio, TX, 6/3/10
Upcoming mesenchymal stem cell trials. Consortium of MS Centers, San Antonio, TX, 6/4/10
ACTRIMS Annual Meeting Session Chair, San Antonio, TX, 6/5/10
MS therapies: where we're going. Mellen Center MS Update, Cleveland, OH, 6/11/10
Update on oral therapies for MS. Research Update, NYC/Southern NY Chapter, National MS Society, New York 9/11/10 and Westchester, 9/12/10
Emerging oral therapies for MS. Huron Hospital Medicine Grand Rounds, Cleveland, OH, 9/13/10
New drugs that affect lymphocytes. 7th Annual Progress in Understanding MS & PD, Asheville, NC, 9/25/10
Highlights: clinical trials. ECTRIMS, Gothenburg, Sweden, 10/16/10
Status report: stems cells and MS. Changing the Future, Mt Sinai-sponsored patient program, New York, NY, 10/24/10
Emerging concepts in MS. Neurology Grand Rounds, University of Pennsylvania, Philadelphia, PA, 12/2/10.
Emerging concepts in MS. Neurology Grand Rounds, Thomas Jefferson University, Philadelphia, PA, 12/3/10

2011

Emerging oral therapies for multiple sclerosis. Neurology Grand Rounds, Pennsylvania State University College of Medicine, Hershey, PA, 1/21/11
Gilenya safety and tolerability profile. Novartis Corporate Therapeutic Update, American Academy of Neurology, Honolulu, HI, 4/12/11
Neurologic diseases: new targets and therapies, Biologic Therapies IV, Cleveland, OH, 5/6/11
Update on stem cells to treat MS. Mellen Center MS Update, Cleveland, OH, 6/24/11
Mesenchymal stem cell transplantation to treat multiple sclerosis, International Society for Cellular Therapy, Charlottesville, VA, 9/16/11
Novel measures of disease progression. ECTRIMS, Amsterdam, The Netherlands, 10/21/11
Update on the cause and treatment of MS. Annual Meeting, Eastern North Carolina Chapter, National MS Society, Raleigh, NC, 10/29/11
Stem cell transplantation to treat MS. Neurology Grand Rounds, University of Minnesota, Minneapolis, MN, 11/3/11

2012

Stems cells to treat MS. Congressional MS Caucus, Washington, DC, 2/1/12
Adult stem cells to treat MS. Cell Society Annual Meeting, San Diego, CA, 2/17/12
Summary of CARE-MS II results. Genzyme investigators meeting, American Academy of Neurology, New Orleans, LA 4/23/12
Results of the CARE-MS II Phase 3 study. American Academy of Neurology, New Orleans, LA, 4/24/12
Phase 1 study of adult mesenchymal stem cell transplantation in multiple sclerosis. American Academy of Neurology, New Orleans, LA, 4/25/12
Fingolimod – utilization and risk management. Course 7TP.002: Therapy of Multiple Sclerosis, American Academy of Neurology, New Orleans, LA, 4/27/12
Mesenchymal stem cell transplantation in multiple sclerosis. Clinical and Scientific Advances in Neuroimmunology – A Tribute to the Multifaceted Career of Dr. Robert Lisak, Wayne State University, Detroit, MI, 5/18/12
Use of mesenchymal stem cells for the treatment of multiple sclerosis. Cell-Based Therapies and Tissue Engineering, Cleveland, OH, 5/21/12
Fingolimod 2 years out: update, Mellen Center MS Update, Cleveland, OH, 6/8/12
Adult stem cell therapy for multiple sclerosis: recent clinical research updates. Living Well with MS patient program, Milwaukee, WI, 8/25/12
Potential improvements in clinical descriptors of MS disease phenotypes, MS Phenotypes consensus conference, New York, NY, 10/26/12

2013

Phase 3 trials of DMTs in progressive MS: endpoints and other aspects of design. International Progressive MS Collaborative, Milan, Italy, 2/7/13
Fingolimod effect on brain atrophy and clinical/MRI correlations in three phase 3 studies – TRANSFORMS,

FREEDOMS and FREEDOMS II. American Academy of Neurology, San Diego, CA 3/21/2013
Utilizing MSC transplantation to treat MS: update on an ongoing phase 1 trial. Workshop on Transplant and Cellular Therapy for Autoimmune Disease, Center for Blood and Marrow Transplant Research, 4/20/13
Use of mesenchymal stem cells to treat multiple sclerosis. Cell-Based Therapies and Tissue Engineering, Cleveland, OH, 5/20/13
Safety of fingolimod in relapsing multiple sclerosis: updated integrated analyses. CMSC/ACTRIMS, Orlando, FL, 6/1/13
New pills for MS: teriflunomide and dimethyl fumarate. Mellen Center Update on MS, Cleveland, OH, 6/21/13
Multiple sclerosis: current and future therapies. Cleveland Clinic 2013 Neurology Update, Washington, DC, 8/2/13
Mesenchymal stem cell transplantation to treat MS. MSC 2013, Cleveland, OH, 8/21/13
Long term benefit of MS treatment. ECTRIMS, Copenhagen, Denmark, 10/3/13
Adult stem cells to treat MS. Annual Meeting, Greater Carolinas Chapter of the National MS Society, Charlotte, NC, 11/2/13
Stem cells. Where do we stand? What's Hot in MS, Ohio Buckeye Chapter of the National MS Society, Cleveland, OH, 11/9/13
Incorporating clinical assessment of visual impairment in MS clinical trial design. International Conference on Vision and Vision-Related Outcomes in MS, Dublin, Ireland, 11/23/13
MSC transplantation to treat MS. NCRM retreat, Cleveland, OH, 12/2/13
Therapeutic strategies for progressive MS: update on an ongoing trial of MSC transplantation. 2013 endMS conference, Saint-Sauveur, Quebec, 12/13/13
Obtaining core measures of disease activity in the future: novel methods. No Evidence of Disease Activity consensus conference, Las Vegas, NV, 12/14/13

2014

Mesenchymal stem cells to treat multiple sclerosis. Future of Cleveland, Naples, FL, 1/30/14
Protocol review. RADIANCE study investigators' meeting, San Diego, CA, 3/7/14
Current and future MS therapies. Multiple Sclerosis Regional Southwestern Forum, Las Vegas, NV, 3/8/14
Current understanding of progressive MS and future directions. National MS Society, Greater Northwest Chapter, Regional MS Summit, Seattle, WA 6/14/14
Phase I trial of intravenous autologous culture expanded mesenchymal stem cell transplantation in multiple sclerosis, Joint ACTRIMS-ECTRIMS Meeting, Boston, MS, 9/11/14
A perspective on generic medications to treat MS, Joint ACTRIMS-ECTRIMS Meeting, Boston, MS, 9/11/14
Generic glatiramer acetate is equivalent to Copaxone on efficacy and safety: results of the randomized, double-blind GATE trial in multiple sclerosis, Joint ACTRIMS-ECTRIMS Meeting, Boston, MS, 9/12/14
Update on MS treatment: medications and stem cells. Annual Meeting, National MS Society, Ohio Buckeye Chapter, Toledo, OH, 11/11/14

2015

Cellular therapy with mesenchymal stem cells for multiple sclerosis. 2015 BMT Tandem Meeting, San Diego, CA, 2/14/15
Results of a phase 1 study of MSC transplantation in multiple sclerosis. National Center for Regenerative Medicine Annual Retreat, Cleveland, OH, 3/6/15
Longterm safety of fingolimod: an interim analysis of the LONGTERMS cohort. American Academy of Neurology, Washington, DC, 4/21/15
2014-2015 Update: multiple sclerosis. American Academy of Neurology, Washington, DC, 4/24/15
Biologics and new therapies for multiple sclerosis. Cleveland Clinic Biologic Therapies VI Summit, Cleveland, OH, 5/1/15
Cellular therapy with mesenchymal stem cells for multiple sclerosis. International Society for Cellular Therapy, Las Vegas, NV, 5/29/15
Stimulating regeneration and repair: viable new approaches? Multiple Sclerosis Management 2105: Redefining Our Approach, Frankfurt, Germany 6/13/15
Considerations in developing a generic MS disease therapy. Mellen Center Update in Multiple Sclerosis, Cleveland, OH, 6/19/15.

Multiple sclerosis: what's new. Cleveland Clinic 2015 Neurology Update, Washington, DC, 8/7/15.
Moderator: The Business of New Drugs and Biologics for Multiple Sclerosis. 2015 Cleveland Clinic
Innovations Summit, Cleveland, OH, 10/27/15.

2016

Medical informatics: utilizing patient-driven mobile technology. Advanced Curriculum in MS, New Orleans,
LA, 2/18/16.

Stem cells in MS: what the clinician needs to know. Neurology Grand Round, Memorial Healthcare,
Hollywood, FL, 6/14/16.

Stem cells in MS: what the clinician needs to know. Mellen Center Update in Multiple Sclerosis, Cleveland,
OH, 6/24/16.

2017

MS therapeutics: what's on the horizon. Mayo Clinic Multiple Sclerosis and Autoimmune Neurology,
Phoenix, AZ, 2/11/17.

Cell-based therapies to treat multiple sclerosis. Neurology Grand Rounds, University of Michigan, Ann Arbor,
MI, 2/15/17.

Considerations in developing a generic MS disease therapy. Glatect Advisory Meeting, Montreal, Canada,
2/17/17.

Results of the GATE trial. Glatect Advisory Meeting, Montreal, Canada, 2/17/17.

Essentials of differential diagnosis and clinical course. Advanced curriculum in MS, Orlando FL, 2/22/17.

Neurodegeneration and remyelination. Advanced curriculum in MS, Orlando FL, 2/23/17.

Medical informatics – utilizing patient driven mobile technology. Advanced curriculum in MS, Orlando FL,
2/22/17.

MSFC and MSOAC.ECTRIMS/Progressive MS Alliance: Advancing trial design in multiple sclerosis, Rome,
IT, 3/9/17.

Diagnostic criteria for MS. Magnetic resonance techniques in multiple sclerosis, Milan, IT, 3/30/17.

Visiting Professorships

1. Department of Neurology, University of Colorado, 7/18/90
2. Department of Neurology, University of Alabama at Birmingham, 11/14/90
3. Department of Neurology, Wayne State University, 11/30/90
4. Department of Neurology, Louisiana State University, 1/11/91
5. Department of Neurology, Medical College of Wisconsin, 12/12/97
6. Department of Neurology, Indiana University, 5/7/98
7. Department of Medicine, Northeast Ohio University College of Medicine, 10/7/98
8. Department of Neurology, University of Kentucky, 11/12/98
9. Department of Neurology, University of Pennsylvania, 1/21/99
10. Department of Neurology, Louisiana State University, 10/22/99
11. Department of Neurology, University of Michigan, 10/10/01
12. Department of Neurology, University of Cincinnati, 5/21/02
13. Department of Neurology, University of Virginia, 12/18/09
14. Department of Neurology, University of Michigan, 2/15/17

Trainees

Post-doctoral fellows:

1. Motomi Arai, MD
2. Cristian Constantinescu, MD PhD
3. Sudhir Batchu, MD
4. Bianca Weinstock-Guttman, MD
5. Mary Rensel, MD
6. Francois Bethoux, MD
7. Robert Fox, MD MSc
8. Ruth Ann Marrie, MD PhD
9. Lori Holland, DO

Years:

1. 1990-1993
2. 1992-1994
3. 1994-1995
4. 1994-1997
5. 1997-1999
6. 1997-2000
7. 2000-2002
8. 2001-2004
9. 2002-2003

Post-fellowship position:

1. Faculty, Niigata Univ.
2. Faculty, Univ. Leicester
3. Private practice
4. Faculty, Univ. Buffalo
5. Staff, CCF
6. Staff, CCF
7. Staff, CCF
8. Staff, CCF
9. Psychiatry Residency, Univ. CO

10. Myla Goldman, MD MSc	2003-2006	Faculty, Univ. Virginia
11. Natasha Frost, MD MSc	2005-2007	Multispecialty group practice
12. Adrienne Boissy, MD MSc	2006-2008	Staff, CCF
13. Robert Bermel, MD	2007-2008	Staff, CCF
14. Devon Conway, MD MSc	2009-2011	Staff, CCF
15. Don Mahad, MD PhD	2010-2011	Consultant, Univ. Edinburgh
16. Daniel Ontaneda, MD MSc	2010-2012	Staff, CCF
17. Megan Hyland, MD MSc	2010-2012	Faculty, Univ. Rochester
18. M Alissa Willis, MD	2011-2012	Staff, CCF
19. Alessandro Serra, MD PhD	2012-2013	Faculty, Case Western Univ.
20. Carrie Hersh, DO	2013-2015	Staff, CCF Las Vegas
21. Geraldine Dapul, MD	2014-2015	Staff, Univ Rochester
22. Ian Rossmann, MD PhD	2014-2016	Akron Childrens Hospital
23. Adnan Subei, DO	2014-2015	Multispecialty group practice
24. Hesham Abboud, MBChB	2015-2016	Faculty, Case Western Univ.
25. Andrew Smith, MD	2015-2017	Pending
26. Burhan Chaudhry, MD	2016-2017	Pending
27. Kedar Mahajan, PD PhD	2016-2018	Pending
28. Marissa McGinley, MD	2016-2018	Pending
29. Brandon Moss, MD	2016-2018	Pending

**CCLCM 2nd Year Clinical Research
Block Preceptorship**

1. Claudiu Diaconu	2008
2. Natasha Mehandru	2012
3. Erik Offerman	2014
4. Carol Swetlik	2015

Teaching Material Produced

None

Teaching Administration

1. Fellowship Director	Clinical Neuroimmunology	1994-present
------------------------	--------------------------	--------------

Teaching Activities at CCF

Neurology Inpatient Service, 1-2 months per year, 1996-2002

Lectures at CCF:

1994

Introduction to MS, Neurology Medical Students, 10/17/94

Treatment of relapsing-remitting MS, Neuroscience Nurses, 11/9/94

1995

Overview of MS, Neurology Medical Students, 3/20/95

Journal Club, Neurology Residents, 4/19/95

Advances in the treatment of MS, Medicine Grand Rounds, 4/27/95

Cardiopulmonary complications of CNS disease, Medicine Residents, 6/1/95

Neurologic complications of immunosuppression, Rheumatology/Immunology conference, 6/12/95

Copolymer-1 in the treatment of relapsing-remitting MS, Neurology Grand Rounds, 7/19/95

Overview of MS, Neurology Medical Students, 10/16/95

1996

Update on clinical trials, Mellen Center, 2/5/96

Nitrous oxide intoxication, Mellen Center, 2/8/96

Immune-based therapies in neurologic disease, Basic and clinical immunology course, 3/18/96

Overview of MS, Neurology Medical Students, 4/15/96
T-cell receptor-based therapy in MS, Mellen Center, 10/10/96
Emerging therapies in MS, Neurology Grand Rounds, 10/16/96
How do we monitor MS?, Myelin Madness, 12/12/96
Clinical anatomy of the spinal cord, Neurology Residents, 12/17/96

1997

Overview of MS, Neurology Medical Students, 2/17/97

1998

MRI in MS, Neurology Grand Rounds, 2/4/98
Journal Club, Neurology Residents, 2/10/98
Update on MS, Medicine Grand rounds (CCF Florida), 4/15/98
Journal Club, Neurology Residents, 9/9/98
Clinical anatomy of the spinal cord I, Neurology Residents, 9/15/98
Differential diagnosis of MS, Rheumatology clinical conference, 9/16/98
Clinical anatomy of the spinal cord II, Neurology Residents, 9/18/98
CPC discussant, Neurology Grand Rounds, 9/30/98

1999

Overview of MS, Medicine Residents, 9/22/99

2001

Treatment of secondary progressive MS, Neurology Grand Rounds, 11/12/01

2003

Clinical features and diagnosis of MS, Neurology Residents, 1/10/03
Interferon beta in secondary progressive MS, Myelin Madness, 2/13/03
Reproductive issues in MS, Neurology Grand Rounds, 2/17/03
Overview of the Neurology Board Exam, Neurology Residents, 6/6/03

2004

Update on the Avonex Combination Trial (ACT), Neurology Grand Rounds, 8/16/04

2005

Clinical features and diagnosis of MS, Neurology Residents, 1/26/05

2006

TNF and demyelinating disease, Neurology Grand Rounds, 1/16/06
Clinical features and diagnosis of MS, Neurology Residents, 3/29/06
Review of Teva 9006 study results, Mellen Clinicians, 6/20/06
Journal Club, Neurology Residents, 8/30/06
Overview of MS, 2nd year Medical Students, 10/4/06

2007

Differential diagnosis of MS, Neurology Residents, 2/13/07
MS case discussion, 3rd year Medical Students, 6/15/07
Overview of MS, 2nd year Medical Students, 10/31/07

2008

Combination therapy in MS, Neurology Grand Rounds, 1/21/08
Changing MS concepts and emerging treatments, Medicine Grand Rounds, 10/2/08

2009

Redirecting lymphocytes in MS, Immunology course, 2/4/09

Overview of MS, Psychiatry Resident Didactic Series, 4/1/09
MS clinical trials, Neurology Resident Didactic Series, 4/15/09

2010

Fingolimod to treat MS, Neurology Grand Rounds, 1/18/10
Aspects of clinical trials, CCLCM Advanced Research in Medicine, 3/26/10
Aspects of clinical trial design, Neurological Institute Resident and Fellow Core Conference Series, 8/18/10
Overview of MS, 2nd year Medical Students, 10/19/10

2011

Stem cell transplantation to treat MS, Neurology Grand Rounds, 4/25/11
Aspects of clinical trial design, Neurological Institute Resident and Fellow Core Conference Series, 8/24/11
MSC transplantation in MS, CCLCM Advances in Research and Medicine, 9/9/11

2012

Aspects of clinical trial design, Neurological Institute Resident and Fellow Core Conference Series, 8/22/12
Overview of MS, 2nd year Medical Students, 10/16/12
Overview of MS, 2nd year Medical Students, 10/17/12

2013

Disease therapies for MS, Neurology Residents, 4/24/13
Aspects of clinical trial design, Neurological Institute Resident and Fellow Core Conference Series, 8/21/13
Overview of MS, 2nd year Medical Students, 10/22/13

2014

Disease therapies for MS, Neurology Residents, 3/14/14
Aspects of clinical trial design, Neurological Institute Resident and Fellow Core Conference Series, 8/20/14
Disease therapies for MS, Neurology Residents, 10/10/14
Overview of MS, 2nd year Medical Students, 10/15/14

2015

Considerations in the development and testing of a generic MS therapy, Neurology Grand Rounds, 1/26/15
Carepaths in MS, Genentech Preceptorship, 3/18/15
Disease therapies for MS, Neurology Residents, 10/12/15
Overview of MS, 2nd year Medical Students, 10/14/15

2016

Overview of MS, Abbvie Preceptorship, 4/12/16
Overview of MS, Abbvie Preceptorship, 5/24/16

2017

Disease therapies for MS, Neurology Residents, 1/6/17

RESEARCH SUPPORT

Grants/Studies (ongoing)

Genzyme, A phase 3, randomized, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three times weekly subcutaneous interferon beta-1a (Rebif) in patients with relapsing-remitting multiple sclerosis who have relapsed on therapy (CARE-MS II), Steering Committee and Site Principal Investigator, 2% effort, 1/08-ongoing extension.

Teva, A multinational, multicenter, randomized, parallel-group, study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety, and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon beta-1a (Avonex) in a rater-blinded design

(BRAVO), Steering Committee and Site Principal Investigator, 2% effort, 3/08-ongoing extension study.

Department of Defense Peer Reviewed Medical Research Program, A phase I assessment of mesenchymal stem cells for the treatment of multiple sclerosis (W81XWH-10-1-0270), Principal Investigator and Steering Committee Chair, 10% effort, 5/15/10-5/14/14.

NINDS, Immunobiology of mesenchymal stem cell transplantation in multiple sclerosis (1 RO1 NS074787), Principal Investigator, 5% effort, 2/1/11-11/30/14.

National MS Society, Institutional Clinician Training Award (ICT 0002), Principal Investigator, 7/1/14-6/30/19.

Receptos, Multicenter, randomized, double-blind study to test the safety and efficacy of a new oral treatment with a potent and selective S1PR agonist (RADIANCE), Coordinating Principal Investigator and Site Principal investigator, 2% effort, 2013-ongoing.

National MS Society, Pilot Research Grant: Labeling of MSCs for in vivo tracking of IV infused MSCs in MS (PP3345), Principal Investigator, 5% effort, 12/1/14-11/30/15.

Grants/Studies (past)

University of Pennsylvania Research Foundation, Neu gene expression in the developing nervous system, Principal Investigator, 7/87-6/88.

University of Pennsylvania School of Medicine Biomedical Research Support Grant, Neu gene expression in the developing nervous system, Principal Investigator, 7/87-6/88.

National MS Society, RG 2093-A-1 Molecular aspects of oligodendrocyte development, Principal Investigator, 4/89-3/92.

Commonwealth of Pennsylvania Legislative Initiative Grant, Methods to modulate myelin synthesis, Principal Investigator, 7/90 - 6/92.

NIH, NS-01284Molecular biology of the beta adrenergic / reovirus receptor (CIDA), Principal Investigator, 4/88 - 3/93.

NIH, NS-08075Expression and function of the neu gene in Schwann cells, Section Principal Investigator, DE Pleasure, Principal Investigator of program project, 12/90 - 11/93.

University of Maryland (Teva), Long-term, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of Copolymer I given subcutaneously in patients with relapsing-remitting multiple sclerosis, Site Principal Investigator, 10/91-4/94.

National MS Society, RG-2091C Quantitative assessment of the impact of clinical trials of Copolymer I on relapsing-remitting multiple sclerosis, Principal Investigator, 10/91-3/94.

Teva Pharmaceuticals, Quantitative assessment of the impact of clinical trials on relapsing-remitting multiple sclerosis, Principal Investigator, 10/91-3/94.

Teva Pharmaceuticals, Supplement to - Quantitative assessment of the impact of clinical trials on relapsing-remitting multiple sclerosis, Principal Investigator, 10/91-3/94.

Athena Neurosciences, A Multicenter Double-blind, Randomized, Placebo-controlled Study to Assess Efficacy and Safety of Tizanidine and the Relationship of Plasma Concentrations to the Changes in Muscle Tone and

Common Adverse Events (AN021-005), Site Principal Investigator, 9/94-12/94.

Athena Neurosciences , A Multicenter, Open-label, Long-term, Study to Evaluate the Safety of Tizanidine Tablets in Patients Suffering from Spasticity Due to Multiple Sclerosis (AN021-002), Site Principal Investigator, 9/94-12/96.

Pharmacia , A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Roquinimex (Linomide) in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis (95LINE145), Site Principal Investigator, 1/96-12/97.

Biogen , A Randomized, Double-blind, Placebo-controlled Study of Avonex (Interferon Beta-1a) in the Treatment of Subjects at High Risk for Development of Multiple Sclerosis Following the First Onset of an Isolated Demyelinating Event (CHAMPS), Site Co-investigator and Endpoint Adjudication Committee, 4/96-4/01.

Connective Therapeutics, Phase I/II trial of safety and immunogenicity of T cell receptor peptide vaccines in patients with multiple sclerosis (TCMS.C.001), Site Principal Investigator, 2/97-11/97.

Schering-Plough, A randomized, double-blinded, placebo-controlled, rising multiple-dose Phase 1b study of subcutaneous rhuIL-10 (SCH 52000) in patients with multiple sclerosis (C97-003), Site Principal Investigator, 3/98-12/98.

Biogen, A tolerability study of Avonex (Interferon beta-1a) in the treatment of subjects with relapsing and secondary progressive multiple sclerosis (C96-823), Site Principal Investigator, 4/97-7/98.

Astra, A Multicenter, Randomized, Placebo-Controlled Double-Blind Study on the Safety and Tolerability of ATM-027 in Patients with Multiple Sclerosis Receiving Single Doses, Site Principal Investigator, 8/99-7/00.

Biogen, A Multi-Center, Open-Label Pharmacodynamic Study of Avonex and Rebif in Multiple Sclerosis Subjects at First Injection and after 12 to 18 Months of Therapy, Site Principal Investigator, 7/99-6/00.

Biogen, A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Avonex in the Treatment of Secondary Progressive Multiple Sclerosis (IMPACT, C97-830), Site Principal Investigator and Coordinating Investigator, 3/98-12/00.

Schering-Plough Research Institute, Pilot MRI Study Of Peg-Intron (Sch 54031) in Ambulatory Subjects with Relapsing Multiple Sclerosis, Site Principal Investigator, 7/99-6/00.

Teva Marion, A Multinational, Multicenter, Randomized, Double-blind, placebo-Controlled, Study to Evaluate the Efficacy, Tolerability, and Safety of 2 Doses (5 mg and 50 mg) of Glatiramer Acetate Orally Administered in Relapsing Remitting Multiple Sclerosis Patients (CORAL, GA/7023), Site Principal Investigator, 1/00-10/01.

Acorda Therapeutics, A Double-blind, Dose-ranging Study of Fampridine-SR in Subjects with Multiple Sclerosis (MS-F201), Site Principal Investigator, 11/00-11/01.

Immunex, A Single 12 mg/m² dose Pharmacokinetic Study of Mitoxantrone Hydrochloride Administered Intravenously in Prostatic Cancer Patients and in Multiple Sclerosis Patients, Site Co-investigator, 7/01-6/02.

Brigham and Women's Hospital/Biogen, Pulse Cyclophosphamide Followed by Treatment with Avonex in Multiple Sclerosis Patients Non-Responsive to Beta-Interferons, Site Principal Investigator, 5/99-10/02.

University of California at San Francisco (Immunex, Serono), A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate Efficacy, Tolerability and Safety of Mitoxantrone in Primary Progressive Multiple Sclerosis, Site Principal Investigator, 1/01-12/03.

University of Maryland (Immunex, Serono), An Open Label Study of the Safety and Efficacy of Combination Therapy with Mitoxantrone (Novantrone) with either Interferon Beta-1a (Avonex) or Glatiramer Acetate (Copaxone), Site Principal Investigator, 11/01-12/03.

Biogen Idec, A Double-blind, Randomized, Placebo-controlled, Parallel-group, Safety Study of Natalizumab in combination with Glatiramer Acetate (GA) in Subjects with Relapsing-remitting Multiple Sclerosis (C-1803), Site Co-investigator, 5/03-5/04.

Biogen Idec, A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in combination with Avonex in Subjects with Relapsing-remitting Multiple Sclerosis (SENTINEL, C-1802), Site Principal Investigator, 11/01-12/04.

Acorda Therapeutics, Double-blind, Placebo-controlled, 20-week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis (MS-F202), Steering Committee and Site Co-investigator, 10/02-5/04.

Merck, A Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-remitting Multiple Sclerosis as Measured by MRI, Site Principal Investigator, 6/04-12/05.

Teva Neuroscience, A multi-center, randomized, double-blind, parallel group study to evaluate the efficacy, tolerability and safety of 40 mg of Copaxone in the treatment of relapsing-remitting multiple sclerosis patients (9006), Steering Committee Chair and Site Principal Investigator, 5% effort, TDC \$44,301, 5/03-12/05.

Pepgen, Phase II open-label, multi-center safety and efficacy study of oral recombinant ovine interferon tau administered daily in patients with relapsing-remitting multiple sclerosis (OvIFN-0102), Data Safety Monitoring Board Chair, 2% effort, 10/03-6/06.

Biogen Idec, A multicenter, randomized, blinded, parallel-group study of Avonex compared with Avonex in combination with oral methotrexate, intravenous methylprednisolone, or both in subjects with relapsing-remitting multiple sclerosis who have breakthrough disease on Avonex monotherapy (C-865), Coordinating Principal Investigator and Director of Coordinating Center, 40% effort, TDC \$23,077,000, 8/02-3/07.

National MS Society PP1278, Optical coherence tomography and diffusion tensor MRI in assessment of visual pathway structure and function following optic neuritis, 5% effort, TDC \$44,000, 8/1/06-7/31/07.

Orchestra Therapeutics, A phase 2 study of NeuroVax, a therapeutic TCR peptide vaccine for multiple sclerosis (IR902-231), Data Safety Monitoring Board Chair, 2% effort, 4/06-8/07.

Teva Neuroscience, A multinational, multicenter, randomized, parallel-group, double-blind, study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40mg/ml and glatiramer acetate injection 20mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) multiple sclerosis (MS) (GA/9016), Co-Coordinating Principal Investigator and Site Principal Investigator, 5% effort, 10/06-10/08.

BioMS, Double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis, Data Safety Monitoring Board, 2% effort, 2/07-10/09.

Immune Tolerance Network (NIAID), A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of atorvastatin in patients with clinically isolated syndrome and high risk of conversion to multiple sclerosis (ITN020A1), Advisory Committee and Site Principal Investigator, 10% effort, TDC \$665,271, 7/03-9/09.

Artielle ImmunoTherapeutics, Double-blind, placebo-controlled, phase 1, dose-escalation study of the safety of

a single dose of RTL 1000 in subjects with relapsing-remitting or secondary progressive multiple sclerosis (1.0001), Data Safety Monitoring Board, 2% effort, 4/06-7/09.

NINDS, 1 K23 NS 47211-01, Brain Atrophy and Diffusion Tensor Studies in Multiple Sclerosis, Consultant, Principal Investigator R Fox, MD, 5% effort, no salary support, TDC \$772,750, 8/04-7/09.

EMD Serono, A phase III randomized, double-blind, placebo-controlled, multicenter trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS (ORACLE), Eligibility Committee, 2% effort, 8/08-8/10.

Biogen Idec, A multicenter, randomized, rater-blinded, parallel-group, active-controlled study to evaluate the benefits of switching therapy (glatiramer acetate or interferon beta-1a) to natalizumab in subjects with relapsing-remitting multiple sclerosis (ASCEND), Site Principal Investigator, 2% effort, 6/10-6/11.

Biogen Idec, Controlled high risk Avonex multiple sclerosis prevention study in ongoing neurological surveillance (C-850), Endpoint Adjudication Committee, 2% effort, TDC \$10,000, 4/01-4/11.

Biogen Idec, JCV antibody program in patients with patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri (STRATIFY-2), Site Principal Investigator, 2% effort, 6/10-2013.

Cleveland Clinic RPC, Characterization of mesenchymal stem cell from healthy control donors (RPC 2012-1017), Principal Investigator, 2% effort, 5/10/2012-5/31/2013.

National MS Society, Pilot Research Grant: Characterization of mesenchymal stem cells from healthy control donors (PP1752), Principal Investigator, 2% effort, 6/1/12-5/31/13.

Novartis, A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon beta-1a (Avonex) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional extension phase” (FTY720D-2302 study), Steering Committee Chair and Site Principal Investigator, 5% effort, 2/06-3/16

Synthon, A multicenter, randomized, double-blind, placebo-controlled, parallel-group, non-inferiority trial comparing the efficacy, safety, and tolerability of GTR (Synthon) to Copaxone (Teva) in subjects with relapsing-remitting multiple sclerosis (GATE), Coordinating Principal Investigator and Site Principal investigator, 2% effort, 8/12-3/16.

Consortium of MS Centers, Pilot Research Grant: Characterization of mesenchymal stem cells from healthy control donors, Principal Investigator, 2% effort, 12/1/12-11/30/13.

Patents:

Method of stimulating myelination of cells, Patent No. 5,219,837, Filed 6/21/90, Issued 6/15/93, Inventors: JA Cohen, MI Greene, WV Williams.

PUBLICATIONS

Peer-reviewed Articles

1. Cohen JA, Essayan DM, Zweiman B, Lisak RP. Limiting dilution analysis of the frequency of antigen-reactive lymphocytes isolated from the central nervous system of Lewis rats with experimental allergic encephalomyelitis. *Cell Immunol* 1987;108:203-213.
2. Hickey WF, Cohen JA, Burns JB. A quantitative immunohistochemical comparison of active versus passive experimental allergic encephalomyelitis in the Lewis rat. *Cell Immunol* 1987;109:272-281.
3. Kokai Y, Cohen JA, Drebin J, Greene MI. Tissue-specific expression of the *neu* oncogene during rat development. *Proc Natl Acad Sci* 1987;84:8498-8501.

4. Cohen JA, Sergott RC, Geller HM, Brown MJ, Greene MI. Mammalian reovirus receptor expression by oligodendrocytes. *Ann NY Acad Sci* 1988;540:445-448.
5. Essayan DM, Cohen JA, Zweiman B, Lisak RP. Effects of OX8+ lymphocytes on in vitro lymphocyte reactivity during experimental allergic encephalomyelitis. *Ann NY Acad Sci* 1988;540:715-717.
6. Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire HC, LiVolsi VA, Greene MI. Expression pattern of the *neu* gene-encoded growth factor receptor protein p185^{neu} in normal and transformed epithelial tissues of the digestive tract. *Oncogene* 1989;4:81-88.
7. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI. The *neu* oncogene: A point mutation mimics ligand induced receptor aggregation. *Nature* 1989;339:230-231.
8. Maguire HC, Jaworsky C, Cohen JA, Hellman M, Weiner DB, Greene MI. The distribution of the *neu* (c-erbB-2) protein in human skin. *J Invest Dermatol* 1989;89:786-790.
9. Williams, WV, Moss DA, Kieber-Emmons T, Cohen JA, Myers JN, Weiner DB, Greene MI. Development of biologically active peptides based on antibody structure. *Proc Natl Acad Sci USA* 1989;86:5537-5541.
10. Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI. Linkage of tyrosine kinase activity with transforming ability in the p185^{neu} oncoprotein. *Oncogene* 1989;4:1175-1183.
11. Cohen JA, Williams WV, Weiner DB, Geller HM, Greene MI. Ligand binding to the cell-surface receptor for reovirus type 3 stimulates surface expression of gactocerebroside by developing oligodendrocytes. *Proc Natl Acad Sci USA* 1990;87:4922-4926.
12. Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA, Kern JA. Expression of the *neu* gene encoded protein (p185^{neu}) in human non-small cell carcinomas of the lung. *Cancer Res* 1990;50:421-5.
13. Cohen JA, Williams WV, More KF, Sehdev H, Davies JG, Greene MI. Ligand binding to the cell-surface receptor for reovirus type 3 alters Schwann cell growth and function. *Ann NY Acad Sci* 1990;605:412-415.
14. Cohen JA, Williams WV, Geller HM, Greene MI. Anti-reovirus receptor antibody accelerates expression of the optic nerve oligodendrocyte developmental program. *Proc Natl Acad Sci USA* 1991;88:1266-1270.
15. Douset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Scarano F, Lavi E, Cohen JA. Experimental allergic encephalomyelitis and multiple sclerosis: Lesion characterization with magnetization transfer imaging. *Radiology* 1992;182:483-491.
16. Cohen JA, Arai M, Luning Prak E, Brooks SA, Young LH, Prystowsky MB. Characterization of a novel mRNA selectively expressed by neurons in mature brain. *J Neurosci Res* 1992;31:273-284.
17. Cohen JA, Sergott RC, Williams WV, Hill SJ, Brown MJ, Greene MI. In vivo modulation of oligodendrocyte function by an anti-receptor antibody. *Pathobiology* 1992;60:151-157.
18. Cohen JA, Yachnis A, Arai M, Davis JG, Scherer SS. Expression of the *neu* proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration. *J Neurosci Res* 1992;31:622-634.
19. Grossman RI, Lenkinski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. *AJNR* 1992;13:1535-1543.
20. Arai M, Prystowsky MB, Cohen JA. Expression of the T-lymphocyte activation gene, F5, by mature neurons. *J Neurosci Res* 1992;33:527-537.
21. Rubin DH, Wetzel JD, Williams WV, Cohen JA, Dworkin C, Dermody TS. Binding of type 3 reovirus by a domain of the sigma 1 protein important for hemagglutination leads to infection of murine erythroleukemia cells. *J Clin Invest* 1992;90:2536-2542.
22. Hill WD, Arai M, Cohen JA, Trojanowski JQ. Neurofilament mRNA is reduced in Parkinson's disease

- substantia nigra pars compacta neurons. *J Comp Neurol* 1993;329:329-336.
23. Cohen JA, Baggott LA, Romano C, Arai M, Southerling TE, Young LH, Kozak CA, Molinoff PB, Greene MI. Characterization of a mouse beta 1-adrenergic receptor genomic clone. *DNA Cell Biol* 1993;12:537-547.
 24. Arai M, Cohen JA. Characterization of the neuroimmune protein F5. Localization to the dendrites and perikarya of mature neurons and the basal aspect of choroid plexus epithelial cells. *J Neurosci Res* 1993;36:305-314.
 25. Arai M, Cohen JA. Subcellular localization of the F5 protein to the neuronal membrane-associated cytoskeleton. *J Neurosci Res* 1994;38:348-357.
 26. Constantinescu CS, West SE, Doty RL, Raps EC, Cohen JA. Olfactory disturbances as the initial or most prominent symptom of multiple sclerosis. *J Neurol Neurosurg Psych* 1994;57:1011-1012.
 27. Grossman M, Armstrong C, Onishi K, Thompson H, Schaefer B, Robinson K, D'Esposito M, Cohen J, Brennan D, Rostami A, Gonzalez-Scarano F, Kolson D, Constantinescu C, Silberberg D. Patterns of cognitive impairment in relapsing-remitting and chronic progressive multiple sclerosis. *Neuropsychiatr Neuropsychol Beh Neurol* 1994;7:194-210.
 28. Hiehle JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: Comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. *AJNR* 1995;16:69-77.
 29. Hiehle JF, Lenkinski RE, Grossman RI, Dousset V, Ramer RN, Schnall MD, Cohen JA, Gonzalez-Scarano F. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. *Magnetic Res Med* 1995;32:285-293.
 30. Autieri MV, Kozak CA, Cohen JA, Prystowsky MB. Genomic organization and genetic mapping of the neuroimmune gene *I2rf5* to mouse chromosome 4. *Genomics* 1995;25:282-284.
 31. Grossman M, Robinson KM, Onishi K, Thompson H, Cohen JA, D'Esposito M. Sentence comprehension in multiple sclerosis. *Acta Neurol Scand* 1995;92:324-331.
 32. Loevner LA, Grossman RI, Cohen JA, Lexa FJ, Kessler D, Kolson DL. Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: Assessment with magnetization-transfer techniques. *Radiology* 1995;196:511-515.
 33. Loevner LA, Grossman RI, McGowan JC, Ramer KN, Cohen JA. Characterization of multiple sclerosis plaques using T1-weighted MR and quantitative magnetization transfer. *AJNR* 1995;16:1473-1479.
 34. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, and the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. *Neurology* 1995;45:1268-1276.
 35. Constantinescu CS, Grossman RI, Finelli PF, Kamoun M, Zmijewski C, Cohen JA. Clinical and subclinical involvement in children of conjugal multiple sclerosis patients. *Mult Scler* 1995;1:170-172.
 36. Petrella JR, Grossman RI, McGowan JC, Campbell G, Cohen JA. Multiple sclerosis lesions: Relationship between MR enhancement pattern and magnetization transfer effect. *AJNR* 1996;17:1041-1049.
 37. Weinstock-Guttman B, Kinkel RP, Cohen JA, Ransohoff RM, Schwetz K, Gogol D, Namey M, Rudick RA. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. *Neurologist* 1997;3:178-185.
 38. Autieri MV, Belkowski SM, Constantinescu CS, Cohen JA, Prystowsky MB. Tissue-specific and inducible expression of potassium channel beta subunits in activated lymphocytes. *J Neuroimmunol* 1997;77:8-16.
 39. Constantinescu CS, Goodman DBP, Grossman RI, Mannon LJ, Cohen JA. Serum angiotensin

converting enzyme in multiple sclerosis. *Arch Neurol* 1997;54:1012-1015.

40. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, O'Connor P, Cohen JA, Schapiro RT, Whitham R, Mass MK, Lindsey JW Shellenberger K. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. *Arch Neurol* 1997;54:731-736.
41. Johnson K, Brooks B, Cohen J, Ford C, Goldstein , Lisak R, Myers L, Panitch H, Rose J, Schiffer R, Vollmer T, Weiner L, Wolinsky J, and the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. *Neurology* 1998;50:701-708.
42. Meier DS, Fisher E, Tkach JA, Masaryk TJ, Cohen JA, Cornhill JF. Automated anatomical labeling of MRI brain data using spatial atlas warping in a finite element framework. *Proceedings of SPIE, Medical Imaging* 1998.
43. Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D. Quantitation of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins. *J Neurochem* 1999;72:741-750.
44. Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. *Epilepsia* 2000;41:148-157.
45. Cohen JA, Fischer JS, Bolibrush DM, Jak AJ, Kniker JE, Mertz LA, Skaramagas TT, Cutter GR. Intrarater and interrater reliability of the MS functional composite outcome measure. *Neurology* 2000;54:802-806.
46. Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarano F, Babb JS, Mannon LJ, Kolson DL, Cohen JA. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment. *Neurology* 2000;54:813-817.
47. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC, and the North American Linomide Investigators. Linomide in relapsing and secondary progressive multiple sclerosis: I. Trial design and clinical results. *Neurology* 2000;54:1726-1733.
48. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC, and the MRI Analysis Center of the University of Texas – Houston Health Science Center for the North American Linomide Investigators. Linomide in relapsing and secondary progressive multiple sclerosis: II. MRI results. *Neurology* 2000;54:1734-1741.
49. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownschidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, and the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. *N Engl J Med* 2000;343:898-904.
50. Liu C, Blumhardt LD, the Copolymer 1 Multiple Sclerosis Study Group. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under/disability time curves. *J Neurol Sci* 2000;181:33-37.
51. Constantinescu CS, Goodman DBP, Hillard B, Wysocka M, Cohen JA. Murine macrophages stimulated with central and peripheral nervous system myelin fragments or proteins release inflammatory products. *Neurosci Letters* 287:171-174, 2000.
52. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak MA, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN, for the IMPACT Investigators. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. *Arch Neurol* 2001;58:961-967.
53. Whitaker JN, Wolinsky JS, Narayana PA, Bartolucci AA, Noseworthy JH, Lublin FD, Linde A, Gjorstrup P, Sullivan HC for the North American Linomide Investigators. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. *Arch Neurol* 2001;58:49-54.
54. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Rudick RA, Sandrok

- AW, Simon JH, Simonian NA, Tsao EC, Whitaker JN, for the IMPACT Investigators. Benefit of intramuscular interferon beta-1a on MSFC progression in secondary progressive MS. *Neurology* 2002;59:679-687.
55. Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandroock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying G-S, Galetta SL, Maguire MG, Cutter GR. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. *Neurology* 2003;61:1367-1373.
56. Marrie RA, Miller DM, Chelune GJ, Cohen JA. Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. *Mult Scler* 2003;9:621-626.
57. Marrie RA, Chelune GJ, Miller DM, Cohen JA. Subjective cognitive complaints relate to mild cognitive impairment in multiple sclerosis. *Mult Scler* 2005;11:69-75.
58. Cree BAC, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL. Clinical characteristics of African American versus Caucasian Americans with multiple sclerosis. *Neurology* 2004;63:2039-2045.
59. Fox RJ, Fisher E, Tkach J, Lee J-C, Cohen JA, Rudick RA. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. *Mult Scler* 2005;11:140-145.
59. Smith DR, , Weinstock-Guttman B, Cohen JA, Guttman C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, Orav J, Stuart W, Weiner H. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active MS on interferon-beta. *Mult Scler* 2005;11:573-582.
60. McFarland HF, Reingold SC on behalf of the National MS Society Advisory Committee on Clinical Trials of New Agents in MS. The future of MS therapies: redesigning MS clinical trials in a new therapeutic era. *Mult Scler* 2005;11:669-676.
61. Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. *Neurology* 2005;64:992-995.
62. Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M, for the IMPACT Investigators. Change in clinician-assessed measures of MS and subject-reported quality of life: results from the IMPACT study. *Mult Scler* 2006;12:180-186.
63. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Marinucci L, Blight AR. Fampridine SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. *Mult Scler* 2007;13:357-368.
64. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. *Neurology* 2007;68:939-944.
65. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. *Mult Scler* 2008;14:383-390.
66. Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WF, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H for the ACT Investigators. Avonex Combination Trial (ACT) in relapsing-remitting MS. Rationale, design, and baseline data. *Mult Scler* 2008;14:370-382.
67. Sergott RC, Frohman E, Glanzman R, Al-Sabbagh A on behalf of the OCT in MS Expert Panel. The role of optical coherence tomography in multiple sclerosis: expert panel consensus. *J Neurol Sci* 2007;263:3-14.
68. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in multiple sclerosis. A reassessment. *Neurology* 2007;70:1134-1140.

69. Goodman AD, Brown TR, [Cohen JA](#), Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR for the Fampridine MS-F202 Study Group. Dose-comparison trial of sustained-release Fampridine in multiple sclerosis. *Neurology* 2008;71:1134-1141.
70. [Cohen JA](#), Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M for the ACT Investigators. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. *Neurology* 2009;72:535-541.
71. Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, [Cohen JA](#), Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O’Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandroock AW, Waubant E. Proof of concept studies for tissue-protective agents in multiple sclerosis. *Mult Scler* 2009;15:542-546.
72. Miller DH, Weinshenker BG, Filippi M, Banwell BL, [Cohen JA](#), Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Mult Scler* 2008;14:1157-1174.
73. Rudick R, Polman C, [Cohen J](#), Walton M, Miller A, Confavreux C, Lublin F, Hutchinson M, O’Connor P, Schwid S, Balcer L, Lynn F, Panzara M, Sandroock A. Assessing disability progression with the Multiple Sclerosis Functional Composite. *Mult Scler* 2009;15:984-997.
74. Reingold SC, Steiner JP, Polman CH, [Cohen JA](#), Freedman MS, Kappos L, Thompson AJ, Wolinsky JS. The challenge of follow-on biologics for treatment of multiple sclerosis. *Neurology* 2009;73:552-559.
75. [Cohen JA](#), Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, for the TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon in relapsing multiple sclerosis. *N Engl J Med* 2010;362:402-415.
76. Darlington PJ, Boivin M-N, Renoux CD, Francois M, Galipeau J, Freedman MS, Atkins HL, [Cohen JA](#), Solchaga L, Bar-Or A. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. *Ann Neurol* 2010;68:540-545.
77. Polman CH, Reingold SC, Banwell B, Clanet M, [Cohen JA](#), Filippi M, Fujihara K, Havrdova E, Hutchinson M, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald Criteria.” *Ann Neurol* 2011;69:292-302.
78. Comi G, [Cohen JA](#), Arnold DL, Wynn D, Filippi M for the FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. *Ann Neurol* 2011;69:75-82.
79. Khatri B, Barkhof F, Comi G, Hartung H-P, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, [Cohen J](#), on behalf of the TRANSFORMS Study Group. Results of a randomized extension of the TRANSFORMS study comparing fingolimod (FTY720) with interferon β -1a in relapsing-remitting multiple sclerosis. *Lancet Neurol* 2011;10:520-529.
80. Waubant E, Pelletier D, Mass M, [Cohen JA](#), Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stuve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS on behalf of the ITN STAYCIS Study Group. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAYCIS study. *Neurology* 2012;78:1171-1178.
81. [Cohen JA](#), Reingold SC, Polman CH, Wolinsky JS, on behalf of the International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcomes in multiple sclerosis clinical trials: current status and future prospects. *Lancet Neurol* 2012;11:467-476.
82. Conway DS, Miller D, O’Brien RG, [Cohen JA](#). Long term benefit of MS treatment: an investigation using a novel data collection technique. *Mult Scler J* 2012;18:1617-1624.
83. Ontaneda D, LaRocca N, Coetzee T, Rudick R on behalf of the NMSS MSFC Task Force. Revisiting the

Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. *Mult Scler J* 2012;18:1074-1080.

84. Ontaneda D, Hara-Cleaver, C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. *J Neurol Sci* 2012;323:167-172.
85. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara M, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet* 2012;380:1819-1828.
86. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox E, Hartung HP, Havrdova E, Selmaj K, Weiner H, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara M, Compston DAS, for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet* 2012;380:1829-1839.
87. Hyland M, Bermel RA, Cohen JA. Restricted diffusion preceding gadolinium enhancement in large or tumefactive demyelinating lesions. *Neurol Clin Pract* 2013;3:15-21.
88. Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, Pelletier J, Eckert B, Haring DA, Francis F, on behalf of the TRANSFORMS Study Group. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. *J Neurol* 2013;260:2023-2032.
89. Francis G, Kappos L, O'Connor P, Collins W, Tang D, Mercier F, Cohen, JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. *Mult Scler J* 2014;20:471-480.
90. Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, Kappos L, Collins W. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. *Neurology* 2014;82:674-680.
91. Khatri B, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: subgroup analyses of the trial assessing injectable interferon versus fingolimod oral in relapsing-remitting multiple sclerosis (TRANSFORMS). *Mult Scler Rel Dis* 2014;3:355-363.
92. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, on behalf of the BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. *J Neurol* 2014;261:773-783.
93. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Soelberg Sorensen P, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetski C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani, MP, Stuve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology* 2014;83:278-286.
94. Serra A, Skelly MM, Jacobs JB, Walker MF, Cohen JA. Improved internuclear ophthalmoparesis with dalfampridine in multiple sclerosis. *Neurology* 2014 83:192-194.
95. Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. *JAMA Neurol* 2014;71:1386-1393.
96. Barkof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, on behalf of the TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. *Mult Scler J* 2014;20:1704-1713.
97. Miller DA, Thompson NR, Cohen JA, Fox RJ, Hartman J, Schwetz K, Conway DS, Rudick RA. Assessment of factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of longitudinal data from a clinical database. *Mult Scler J* 2015;21:457-465.

98. DiMarco JP, O'Connor P, [Cohen JA](#), Reder AT, Zhang-Auberson L, Tang D, Collins W, Kappos L. First-dose effects of fingolimod: pooled safety data from three Phase 3 studies. *Mult Scler Related Disorders* 2014;3:629-638.
99. Kappos L, [Cohen J](#), Collins W, de Vera A, Zhang-Auberson L, Ritter S, von Rosenstiel P, Francis G. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. *Mult Scler Related Disorders* 2014;3:494-504.
100. Hersh CM, Hara-Cleaver C, Rudick RA, [Cohen JA](#), Bermel RA, Ontaneda D. Experience with fingolimod in clinical practice. *Int J Neurosci* 2015;125:678-685.
101. Balcer LJ, Miller DH, Reingold SC, [Cohen JA](#). Vision and vision-related outcome measures in multiple sclerosis. *Brain* 2015;138:11-27.
102. Radue EW, Barkhof F, Kappos L, Sprenger T, Haring DA, de Vera A, von Rosenstiel P, Bright JR, Francis G, [Cohen JA](#). Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. *Neurology* 2015;84:784-793.
103. Marrie RA, Reider N, [Cohen J](#), Stuve O, Trojano M, Soelberg Sorensen P, Cutter G, for the International Advisory Committee on Clinical Trials in MS. A Systematic Review of the Incidence and Prevalence of Comorbidity in Multiple Sclerosis: Overview. *Mult Scler J* 2015;21:263-281.
104. Marrie RA, Reider N, [Cohen J](#), Stuve O, Soelberg Sorensen P, Cutter G, Trojano M, for the International Advisory Committee on Clinical Trials in MS. A Systematic Review of the Incidence and Prevalence of Autoimmune Disease in Multiple Sclerosis. *Mult Scler J* 2015;21:282-293.
105. Marrie RA, Reider N, [Cohen J](#), Stuve O, Trojano M, Soelberg Sorensen P, Cutter G, for the International Advisory Committee on Clinical Trials in MS. A Systematic Review of the Incidence and Prevalence of Cancer in Multiple Sclerosis. *Mult Scler J* 2015;21:294-304.
106. Marrie RA, [Cohen J](#), Stuve O, Trojano M, Soelberg Sorensen P, Cutter G, Reider N, for the International Advisory Committee on Clinical Trials in MS. The Incidence and Prevalence of Psychiatric Disorders in Multiple Sclerosis: A Systematic Review. *Mult Scler J* 2015;21:305-317.
107. Marrie RA, Reider N, [Cohen J](#), Stuve O, Trojano M, Cutter G, Soelberg Sorensen P, for the International Advisory Committee on Clinical Trials in MS. A Systematic Review of the Incidence and Prevalence of Cardiac, Cerebrovascular and Peripheral Vascular Disease in Multiple Sclerosis. *Mult Scler J* 2015;21:318-331.
108. Marrie RA, Reider N, Stuve O, Trojano M, Soelberg Sorensen P, Cutter G, [Cohen J](#), for the International Advisory Committee on Clinical Trials in MS. The Incidence and Prevalence of Comorbid Gastrointestinal, Musculoskeletal, Ocular, Pulmonary, and Renal disorders in Multiple Sclerosis: A Systematic Review. *Mult Scler J* 2015;21:332-341.
109. Marrie RA, Reider N, [Cohen J](#), Trojano M, Soelberg Sorensen P, Cutter G, Stuve O, for the International Advisory Committee on Clinical Trials in MS. A Systematic Review of the Incidence and Prevalence of Sleep Disorders and Seizure Disorders in Multiple Sclerosis. *Mult Scler J* 2015;21:342-349.
110. Isobe N, Madireddy L, Khankhansian P, Matsushita T, Caillier SJ, More JM, Gourraud P-A, McCauley JL, Beecham A, International MS Genetics Consortium, Piccio L, Herbert J, Khan O, [Cohen J](#), Stone L, Santaniello A, Cree BAC, Onengut-Gumuscu S, Rich SS, Hauser SL, Sawcer S, Oksenberg JR. An ImmunoChip study of multiple sclerosis risk in African Americans. *Brain* 2015;138:1518-1530.
111. [Cohen JA](#), Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L, on behalf of the TRANSFORMS (*TR*ial Assessing injectable interfero*N* v*S*. *FTY*720 Oral in *RRMS*) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the Extension phase of the TRANSFORMS study. *J Neurol Neurosurg Psychiatr* 2016;87:468-475.
112. [Cohen JA](#), Belova A, Selmaj K, Wolf C, Oberyé J, van den Tweel E, PhD, Mulder R, Koper N, Voortman G, Barkhof F, for the GATE Study Group. Equivalence of generic glatiramer acetate in multiple sclerosis. *JAMA Neurol* 2015;72:1433-1441.

113. Cree BA, Bennett JL, Sheehan M, [Cohen JA](#), Hartung HP, Aktas O, Kim HJ, Friedemann P, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. A placebo-controlled study in neuromyelitis optica – ethical and design considerations. *Mult Scler J* 2016;22:862-872.
114. Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold, [Cohen JA](#) for the attendees of the International workshop on Comorbidity in Multiple Sclerosis. The challenge of comorbidity in clinical trials in multiple sclerosis. *Neurology* 2016;86:1446-1453.
115. Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold, Fiest K, Reider N, [Cohen JA](#) for the attendees of the International workshop on Comorbidity in Multiple Sclerosis. Recommendations for observational studies of comorbidity in clinical trials in multiple sclerosis. *Neurology* 2016;86:1437-1445.
116. [Cohen JA](#), Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, and Selmaj KW, for the RADIANCE Study Group. Efficacy and safety of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis. *Lancet Neurol* 2016;15:373-381.
117. Cadavid D, [Cohen JA](#), Freedman S, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive MS. *Mult Scler J* Published online before print March 22, 2016 as doi:10.1177/1352458516638941.
118. Conway DS, Thompson NR, [Cohen JA](#). Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. *Mult Scler J* Published online before print May 26, 2016 as doi:10.1177/1352458516650512.
119. Rozenberg A, Rezk A, Boivin M-N, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, [Cohen JA](#), Bar-or A. Human mesenchymal stem cells impact Th17 and Th1 responses through a PGE2- and myeloid-cell-dependent mechanism. *Stem Cells Transl Med* (in press).
120. Arnold DL, Fisher E, Brtinar VV, [Cohen JA](#), Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Cinar A, Margolin DH, Thomas DR, Panzara MA, Compston DAS on behalf of the Care MS I and Care MS II Investigators. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in multiple sclerosis. *Neurology* 2016 87:1464-1472.
121. Sormani MP, Kappos L, Radue EW, [Cohen JA](#), Barkhof F, Sprenger T, Meier DP, Häring D, Tomic D, De Stefano N. Defining individualized brain volume to predict disability worsening in RRMS patients. *Mult Scler J* Published online before print July 13, 2016 as doi:10.1177/1352458516659550.
122. Giovannoni G, [Cohen JA](#), Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Panzara MA, Compston, on behalf of the CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. *Neurology* 2016 87:1985-1992.
123. Conway DS, Thompson NR, [Cohen JA](#). Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: an evaluation using electronically collected outcomes. *Mult Scler Rel Dis* 2016;9:129-34.
124. Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, [Cohen JA](#), Ontaneda D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. *Mult Scler Rel Dis* 2016;10:44-52.
125. Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, We C-Hi, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ, Aktas O, Amezcua L, Apiwattanakul M, Asgari N, Banwell B, Bennett J, Bowen JD, Cabre P, Chitnis T, [Cohen JA](#), de Seze J, Fujihara K, Han M, Hellwig K, Hintzen RQ, Hooper D, Iorio R, Jacob A, Jarius S, Kim HJ, Kissani N, Klawiter E, Kleiter I, Lana-Peixoto M, Leite MI, Levy M, Lublin FD, Draayer Y, Marignier R, Matiello M, Nakashima I, Palace J, Pandit L, Friedemann P, Prayoonwiwat N, Riley C, Ruprecht K, Saiz A, Siritho S, Tenenbaum S, Weinshenker B, Wingerchuk D, and Wuerfel J.

Restoring immune tolerance in neuromyelitis optica. *Neurology Neuroimmunol Neuroinflamm* 2016;3:e276; doi: 10.1212/NXI.0000000000000276.

126. Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, We C-Hi, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ, Aktas O, Amezcua L, Apiwattanakul M, Asgari N, Banwell B, Bennett J, Bowen JD, Cabre P, Chitnis T, Cohen JA, de Seze J, Fujihara K, Han M, Hellwig K, Hintzen RQ, Hooper D, Iorio R, Jacob A, Jarius S, Kim HJ, Kissani N, Klawiter E, Kleiter I, Lana-Peixoto M, Leite MI, Levy M, Lublin FD, Draayer Y, Marignier R, Matiello M, Nakashima I, Palace J, Pandit L, Friedemann P, Prayoonwiwat N, Riley C, Ruprecht K, Saiz A, Siritho S, Tenenbaum S, Weinshenker B, Wingerchuk D, and Wuerfel J. Restoring immune tolerance in neuromyelitis optica. *Neurology Neuroimmunol Neuroinflamm* 2016;3:e277; doi: 10.1212/NXI.0000000000000277.
 127. Dickerson E, Davenport M, Syed F, Stuve O, Cohen J, Rinker J, Goldman M, Michigan Radiology Quality Collaborative, Foerster B. Effect of template reporting of brain MRIs for multiple sclerosis on report thoroughness and neurologist perception of report quality: results of a prospective quality improvement project. *JACR* (in press).
 128. Selmaj K, Barkhof F, Belova A, Wolf C, van den Tweel ERW, Oberyé JIL, Mulder R, Egging DF, Koper NP, Cohen JA on behalf of the GATE study group. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. *Mult Scler J* published online 16 JAN 2017 DOI: 10.1177/1352458516688956.
 129. Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick RA. Validity of the Timed 25-Foot Walk as an ambulatory performance outcome measure for multiple sclerosis. *Mult Scler J* published online 16 Feb 2016 DOI: 10.1177/1352458517690823.
 130. Havrdova E, Arnold DL, Cohen JA, Hartung H-P, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Panzara MA, Coles AJ on behalf of CARE-MS I and CAMMS03409 Investigators. Alemtuzumab CARE-MS I 5 year follow-up: Durable efficacy in the absence of continuous MS therapy. *Neurology* (in press).
 131. Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. *Mult Scler J* (in press).
- Coles AJ, Cohen JA, Giovannoni G, Hartung H-P, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Margolin DH, Thangavelu K, Chiriac MC, Jody D, Xenopoulos P, Panzara MA, Arnold DL on behalf of CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5 year follow-up: Durable efficacy in the absence of continuous MS therapy. *Neurology* (submitted).
- Scolding NJ, Pasquini M, Reingold SC, Cohen JA. Cell-based therapeutic strategies for multiple sclerosis. *Brain* (submitted).
- Sargent A, Bai L, Shano G, Karl M, Garrison E, Ranasinghe L, Planchon S, Cohen J, Miller R. CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. *Nat Commun* (submitted).
- Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: a case report. *Mult Scler Rel Dis* (submitted).
- Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, fox RJ, Cohen JA, Ontaneda D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. *Mult Scler J* (submitted).

Edited Books, Monographs, or Journal Volumes

1. Cohen JA and Rudick RA (eds). *Multiple Sclerosis Therapeutics, 2nd Edition*. Martin Dunitz, London, 2003.

2. Cohen JA and Rudick RA (eds). *Multiple Sclerosis Therapeutics, 3rd Edition*. Informa Healthcare, London, 2007.
3. Cohen JA and Rae-Grant A. *Handbook of Multiple Sclerosis*. Springer Healthcare, London, 2010.
4. Cohen JA and Rudick RA (eds). *Multiple Sclerosis Therapeutics, 4th Edition*. Cambridge University Press, Cambridge, 2011.
5. Cohen JA and Rae-Grant A. *Handbook of Multiple Sclerosis*. Springer Healthcare, London, 2012.

Invited Reviews

1. Greene MI, Kokai Y, Gaulton GN, Powell MB, Geller H, Cohen JA. Receptor systems in tissues of the nervous system. *Immunol Rev* 1987;100:153-184.
2. Cohen JA, Williams WV, Greene MI. Molecular aspects of reovirus-host cell interaction. *Microbiol Sci* 1988;9:265-270.
3. Williams WV, Guy HR, Cohen JA, Weiner DB, Greene MI. Molecular and immunologic analyses of a functional internal image formed by an anti-receptor antibody. *Ann Immunol* 1988;139:659-675.
4. Myers JN, Kokai Y, Cohen JA, Greene MI. Monoclonal antibodies to oncogene encoded proteins: Immunologic modulation of cell growth, differentiation, and function. *Year in Immunol* 1989;5:178-194.
5. Williams WV, Weiner DB, Cohen JA, Greene MI. Development and use of receptor binding peptides derived from antireceptor antibodies. *Biotechnology* 1989;7:171-175.
6. Williams WV, Moss DA, Weiner DB, Cohen JA, Guy HR, Greene MI. Anti-idiotypic modeled peptides with biologic activity. *Adv Immunopharm* 1989;4:119-126.
7. Cohen JA, Williams WV, Weiner DB, Greene MI. Molecular aspects of ligand interaction with somatic and immune receptors: Insights from studies of the mammalian reoviruses. *Chemical Immunol* 1989;46:126-156.
8. Williams WV, Guy HR, Cohen JA, Weiner DB, Greene MI. Structure and regulation of internal image idiotypes. *Chemical Immunol* 1990;48:185-208.
9. Constantinescu CS, Cohen JA. Regulatory cytokine therapy for autoimmune disease. Implications for multiple sclerosis. *Multiple Sclerosis Clinical Issues* 1994;1:6-9.
10. Cohen JA, Raps EC. Critical neurologic illness in the immunocompromised patient. *Neurol Clinics* 1995;13:659-675.
11. Weinstock-Guttman B, Cohen JA. Newer versus older treatments for relapsing-remitting multiple sclerosis. *Drug Safety* 1996;14:121-130.
12. Weinstock-Guttman B, Cohen JA. Emerging therapies for multiple sclerosis. *Neurologist* 1996;2:342-355.
13. Weinstock-Guttman B, Nair D, Cohen JA. Neurologic complications of immunosuppressive and anti-inflammatory therapy for rheumatic diseases. *J Clin Rheum* 1996;2:268-278.
14. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. *N Engl J Med* 1997;337:1604-1611.
15. Cohen JA, Carter JL, Kinkel RP, Schwid SR. Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. *J Neuroimmunol* 1999;98:29-36.
16. Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin FD, Paty DW, Rice GP, Weinstock-Guttman B. Multiple sclerosis. *Continuum* 1999;5:1-196.
17. Bethoux FA, Cohen JA. Diagnosis and treatment of multiple sclerosis. *Curr Opinions Orthop* 1999;10:492-497.
18. Rensel MR, Cohen JA. Current approaches to managing multiple sclerosis. Early diagnosis, early

treatment, close monitoring. *Women Health Primary Care* 2000;3:417-431.

19. Fox RJ, Cohen JA. Multiple sclerosis: The importance of early recognition and treatment. *Cleve Clin J Med* 2001;68:157-171.
20. Weiner HA, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: Critical review of clinical and immunologic effects. *Mult Scler* 2002;8:142-154.
21. Marrie RA, Cohen JA. An appraisal of the Multiple Sclerosis Functional Composite. *Expert Rev Neurotherapeutics* 2003;3:335-341.
22. Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: pathogenesis, diagnosis, and disease treatment. *Cleve Clin J Med* 2006;73:91-102.
23. Goldman MD, Cohen JA, Fox RJ, Bethoux F. Multiple sclerosis: symptomatic treatment approaches and general medical issues. *Cleve Clin J Med* 2006;73:177-186.
24. Boissy AR, Cohen JA. Multiple sclerosis symptom management. *Expert Rev Neurotherapeutics* 2007;7:1213-1222.
25. Bermel RA, Fisher E, Cohen JA. The use of MRI as an outcome measure in multiple sclerosis clinical trials. *Neuroimag Clin NA* 2008;18:687-701.
26. Cohen JA. Emerging therapies for relapsing multiple sclerosis. *Arch Neurol* 2009;66:821-828.
27. Cohen JA. The future of multiple sclerosis treatment. *J Neurol Sci* 2009;277(S1):S55-S61.
28. Conway D, Cohen JA. Combination therapy in multiple sclerosis. *Lancet Neurol* 2010;9:299-308.
29. Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. *Curr Neurol Neurosci Rep* 10:381-388, 2010.
30. Bermel RA, Cohen JA. 2010 Roundup. Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. *Lancet Neurol* 2011;10:4-5.
31. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. *Ann Neurol* 2011;69:759-777.
32. Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: news insights in pathogenesis and novel therapeutics. *Ann Rev Med* 2012;63:389-404.
33. Hyland MH, Cohen JA. New drug/device: fingolimod. *Neurol Clin Pract* 2011;1:61-65.
34. Ontaneda D, Cohen JA. Key paper evaluation: potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). *Expert Rev Clin Pharmacol* 2011;4:567-570.
35. Auletta JJ, Bartholomew AM, Maziarz R, Deans RJ, Miller RH, Lazarus HM, Cohen JA. The potential of mesenchymal stromal cells as novel cellular therapy for multiple sclerosis. *Immunotherapy* 2012;4:529-547. PMID: PMC3381871 NIHMSID: NIHMS384437
36. Cohen JA. Ethical issues of placebo-controlled clinical trials in multiple sclerosis. *Clin Invest* 2012;2:351-354.
37. Cohen JA. Mesenchymal stem cell transplantation in multiple sclerosis. *J Neurol Sci* 2013;333:43-49.
38. Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. *Semin Neurol* 2013;33:37-44.
39. Hersh CM, Cohen JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. *Immunotherapy* 2014;6:249-259.
40. Rossman I, Cohen JA. Cell based therapeutic strategies in multiple sclerosis. *Eur Rev Neurol* 2014;9:37-43.
41. Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. *CNS Drugs* 2015;29:565-575.
42. Hua LH, Cohen JA. Considerations in the development of generic disease therapies for multiple sclerosis. *Neurol Clin Pract* 2016;6:369-376.

43. Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. *Lancet* 2017;389(10076):1357-1366.
44. McGinley MP, Moss BP, Cohen JA. Safety of monoclonal antibodies for the treatment of multiple sclerosis. *Expert Op Drug Safety* 2016;31:1-12.

Book Chapters

1. Cohen JA, Lisak RP. Acute disseminated encephalomyelitis. In: *Neuroimmunology for the Clinician*. Aarli JA, Behan WMH, Behan PO (eds). Blackwell Scientific Publishers, 1987.
2. Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen JA, Hamuro J, Weiner DB, Greene MI. The role of the neu oncogene product in cell transformation and normal development. In: *Immune System and Cancer*. Hamoka et al (eds). Japan Sci. Soc. Press, 1989.
3. Cohen JA, Williams WV, Greene MI. Antigenic structure of reoviruses. In: *Immunochemistry of Viruses II*. Neurath RA and Van Regenmortel MVH (eds). Elsevier Biomedical Press, 1990.
4. Cohen JA, Rudick RA. Classification and diagnosis of multiple sclerosis. In: *Clinical Neuroimmunology*. Johnson KP and Panitch H (eds). Williams and Wilkins, 1994.
5. Cookfair DL, Weinstock-Guttman B, Cohen JA. Multiple sclerosis: Experience with large clinical trials. In: *Clinical Trials in Neurology*. Guiloff RJ (ed). Springer-Verlag, 2001.
6. Cohen JA, Rensel MR. The differential diagnosis of multiple sclerosis and clues to misdiagnosis. In: *Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation*. Burks JS, Johnson KP (eds). Demos Vermande, 2000.
7. Cohen JA, Rudick RA. Aspects of multiple sclerosis that relate to clinical trial design and treatment. In: *Multiple Sclerosis Therapeutics, 2nd Edition*. Cohen JA, Rudick RA (eds). Martin Dunitz, 2003.
8. Marrie RA, Cohen JA. Interferons in secondary progressive multiple sclerosis. In: *Multiple Sclerosis Therapeutics, 2nd Edition*. Cohen JA, Rudick RA (eds). Martin Dunitz, 2003.
9. Goldman MD, Cohen JA. *Multiple Sclerosis*. In: Conn's Current Therapy. Rakel RE, Bope ET (eds). WB Saunders Company. 2005.
10. Cohen JA, Rudick RA. Aspects of multiple sclerosis that relate to trial design and clinical treatment. In: *Multiple Sclerosis Therapeutics, 3rd Edition*. Cohen JA, Rudick RA (eds). Informa Healthcare, 2007.
11. Marrie RA, Cohen JA. Interferons in secondary progressive multiple sclerosis. In: *Multiple Sclerosis Therapeutics, 3rd Edition*. Cohen JA, Rudick RA (eds). Informa Healthcare, 2007.
12. Cohen JA, Confavreux C. Combination therapy in multiple sclerosis. In: *Multiple Sclerosis Therapeutics, 3rd Edition*. Cohen JA, Rudick RA (eds). Informa Healthcare, 2007.
13. Samkoff LM, Cohen JA, Goodman AD. Disease modifying therapy for multiple sclerosis in clinical practice. In: *Multiple Sclerosis Therapeutics, 3rd Edition*. Cohen JA, Rudick RA (eds). Informa Healthcare, 2007.
14. Rudick RA, Cohen JA. Aspects of multiple sclerosis that relate to experimental therapeutics. In: *Multiple Sclerosis Therapeutics, 4th Edition*. Cohen JA, Rudick RA (eds). Cambridge University Press, 2011.
15. Bermel RA, Fisher E, Imrey PB, Cohen JA. The use of MRI in multiple sclerosis clinical trials. In: *Multiple Sclerosis Therapeutics, 4th Edition*. Cohen JA, Rudick RA (eds). Cambridge University Press, 2011.
16. Cohen JA. Fingolimod to treat multiple sclerosis. In: *Multiple Sclerosis Therapeutics, 4th Edition*. Cohen JA, Rudick RA (eds). Cambridge University Press, 2011.
17. Mahad D, Planchon SM, Cohen JA. Mesenchymal stem cell transplantation to treat multiple sclerosis. In: *Multiple Sclerosis Therapeutics, 4th Edition*. Cohen JA, Rudick RA (eds). Cambridge University

Press, 2011.

18. Cohen JA, Goodman AD. Disease-modifying therapy for multiple sclerosis in clinical practice. In: *Multiple Sclerosis Therapeutics, 4th Edition*. Cohen JA, Rudick RA (eds). Cambridge University Press, 2011.
19. Hyland MH, Cohen JA. Differential diagnosis of multiple sclerosis. In: *Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation*. Rae-Grant A, Fox RJ, and Bethoux F (eds). Demos, 2013.
20. Hyland MH, Cohen JA. Progressive MS treatment algorithms. In: *Multiple Sclerosis and CNS Neuroimmunologic Disorders*. Samkoff L, Goodman A (eds). Wiley Blackwell, 2014.

Audio/Video/CD-Rom, etc.

None

Editorials/Commentaries/Book Reviews

1. Review of *The Molecular Biology of Neurological Disease*. Edited by Rosenberg RN and Harding AE. London, Butterworths, 1988. *Ann Neurol* 1989;26:795-796.
2. Review of *Magnetic Resonance Imaging in Multiple Sclerosis. An Atlas of Diagnosis and Differential Diagnosis*. Kesselring J, Ormerod IEC, Miller DH, du Boulay EPGH, McDonald WI. New York, Thieme Medical Publishers, 1989. *Ann Neurol* 1990;28:397.
3. Review of *Clinical Neurology A Modern Approach*. Hopkins A. Oxford, Oxford Press, 1993. *Neurology* 1994;44:1989.
4. Review of *Primary Progressive Multiple Sclerosis*. Edited by Filippi M and Comi G. Milan, Springer Verlag Italia, 2002. *Neurology* 2002
5. Cohen JA, Antel JP. Does interferon beta help in secondary progressive MS? (editorial) *Neurology* 2004;63:1768-1769.
6. Goldman MD, Cohen JA. Statins to treat multiple sclerosis. Friend or foe? (editorial) *Neurology* 2008;71:1386-1387.
7. Cohen JA. How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis? (practice point). *Nature Clin Practice Neurol* 2008;4:588-589.
8. Cohen JA. Corticosteroids in combination therapy for multiple sclerosis (Reflection and Reaction). *Lancet Neurol* 2009;8:502-503.
9. Conway D, Cohen JA. News & Views: Mechanisms of disability accumulation in multiple sclerosis. *Nature Rev Neurol* 2010;6:654-655.
10. Freedman MS, Cohen JA. Meta-analysis of bone marrow transplantation treatment studies: mixing apples and oranges. *Mult Scler* 2011;17:131-132.
11. Ontaneda D, Cohen JA. EDSS improvement: Recovery of function or noise? *Mult Scler J* 2012;18:1520-1521.
12. Ontaneda D, Cohen JA. The benefits and risks of alemtuzumab in multiple sclerosis. *Exp Rev Clin Immunol* 2013;9:189-91.
13. Rossman IT, Cohen JA. Commentary on Classic Paper: "Rivers T, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. *J Exp Med* 1933; 58:39-53." <http://www.msdiscovery.org/papers/classic-papers>.
14. Heesen C, Cohen JA. Does the patient know best? Quality of life assessment in multiple sclerosis trials. *Mult Scler J* 2014;20:131-132.
15. Bourdette DN, Cohen JA. Venous angioplasty for "CCSVI" in multiple sclerosis: ending a therapeutic misadventure. *Neurology* 2014;83:388-389.

16. Conway DS, Cohen JA. Natalizumab and fingolimod: insight into their relative efficacies in clinical practice. *Mult Scler J* 2014;20:1280-1281.
17. Rossman IT, Cohen JA. Switching sides – fingolimod versus injectable MS therapies. *Nature Rev Neurol* 2015;11:316-317.
18. Rossman IT, Cohen JA. Should MRI be the primary endpoint in phase 3 trials in multiple sclerosis? *Exp Rev Clin Immunol* 2016;12:489-491.
19. Smith AL, Cohen JA. Fingolimod failure in MS INFORMS future trials. *Nature Rev Neurol* 2016;12:253-254.

Letters

1. Rooney RN, Kotze MJ, de Villiers JNP, Hillerman R, Cohen JA. Multiple sclerosis, porphyria-like symptoms and a history of iron deficiency anemia in a family of Scottish descent (letter). *Am J Med Genet* 1999;86:194-196.
2. Cohen JA, Chun J. Reply to “Fingolimod treatment for MS patients. What do we do with Varicella?” *Ann Neurol* 2011;70:674.

Published Abstracts

Not listed